1
|
van der Voort A, van der Hoogt KJJ, Wessels R, Schipper RJ, Wesseling J, Sonke GS, Mann RM. Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer. Eur Radiol 2024:10.1007/s00330-024-10857-7. [PMID: 38967659 DOI: 10.1007/s00330-024-10857-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Revised: 04/15/2024] [Accepted: 04/26/2024] [Indexed: 07/06/2024]
Abstract
OBJECTIVES The aim of this study is to investigate the added value of diffusion-weighted imaging (DWI) to dynamic-contrast enhanced (DCE)-MRI to identify a pathological complete response (pCR) in patients with HER2-positive breast cancer and radiological complete response (rCR). MATERIALS AND METHODS This is a single-center observational study of 102 patients with stage I-III HER2-positive breast cancer and real-world documented rCR on DCE-MRI. Patients were treated between 2015 and 2019. Both 1.5 T/3.0 T single-shot diffusion-weighted echo-planar sequence were used. Post neoadjuvant systemic treatment (NST) diffusion-weighted images were reviewed by two readers for visual evaluation and ADCmean. Discordant cases were resolved in a consensus meeting. pCR of the breast (ypT0/is) was used to calculate the negative predictive value (NPV). Breast pCR-percentages were tested with Fisher's exact test. ADCmean and ∆ADCmean(%) for patients with and without pCR were compared using a Mann-Whitney U-test. RESULTS The NPV for DWI added to DCE is 86% compared to 87% for DCE alone in hormone receptor (HR)-/HER2-positive and 67% compared to 64% in HR-positive/HER2-positive breast cancer. Twenty-seven of 39 non-rCR DWI cases were false positives. In HR-negative/HER2-positive breast cancer the NPV for DCE MRI differs between MRI field strength (1.5 T: 50% vs. 3 T: 81% [p = 0.02]). ADCmean at baseline, post-NST, and ∆ADCmean were similar between patients with and without pCR. CONCLUSION DWI has no clinically relevant effect on the NPV of DCE alone to identify a pCR in early HER2-positive breast cancer. The added value of DWI in HR-positive/HER2-positive breast cancer should be further investigated taken MRI field strength into account. CLINICAL RELEVANCE STATEMENT The residual signal on DWI after neoadjuvant systemic therapy in cases with early HER2-positive breast cancer and no residual pathologic enhancement on DCE-MRI breast should not (yet) be considered in assessing a complete radiologic response. KEY POINTS Radiologic complete response is associated with a pathologic complete response (pCR) in HER2+ breast cancer but further improvement is warranted. No relevant increase in negative predictive value was observed when DWI was added to DCE. Residual signal on DW-images without pathologic enhancement on DCE-MRI, does not indicate a lower chance of pCR.
Collapse
Affiliation(s)
- Anna van der Voort
- Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.
| | - Kay J J van der Hoogt
- Department of Radiology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
- GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Ronni Wessels
- Department of Radiology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Robert-Jan Schipper
- Department of Radiology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
- Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands
| | - Jelle Wesseling
- Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Gabe S Sonke
- Department of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
- University of Amsterdam, Amsterdam, The Netherlands
| | - Ritse M Mann
- Department of Radiology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| |
Collapse
|
2
|
Kim JY, Partridge SC. Non-contrast Breast MR Imaging. Radiol Clin North Am 2024; 62:661-678. [PMID: 38777541 PMCID: PMC11116814 DOI: 10.1016/j.rcl.2023.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2024]
Abstract
Considering the high cost of dynamic contrast-enhanced MR imaging and various contraindications and health concerns related to administration of intravenous gadolinium-based contrast agents, there is emerging interest in non-contrast-enhanced breast MR imaging. Diffusion-weighted MR imaging (DWI) is a fast, unenhanced technique that has wide clinical applications in breast cancer detection, characterization, prognosis, and predicting treatment response. It also has the potential to serve as a non-contrast MR imaging screening method. Standardized protocols and interpretation strategies can help to enhance the clinical utility of breast DWI. A variety of other promising non-contrast MR imaging techniques are in development, but currently, DWI is closest to clinical integration, while others are still mostly used in the research setting.
Collapse
Affiliation(s)
- Jin You Kim
- Department of Radiology and Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
| | - Savannah C Partridge
- Department of Radiology, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA.
| |
Collapse
|
3
|
Gullo RL, Partridge SC, Shin HJ, Thakur SB, Pinker K. Update on DWI for Breast Cancer Diagnosis and Treatment Monitoring. AJR Am J Roentgenol 2024; 222:e2329933. [PMID: 37850579 PMCID: PMC11196747 DOI: 10.2214/ajr.23.29933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2023]
Abstract
DWI is a noncontrast MRI technique that measures the diffusion of water molecules within biologic tissue. DWI is increasingly incorporated into routine breast MRI examinations. Currently, the main applications of DWI are breast cancer detection and characterization, prognostication, and prediction of treatment response to neoadjuvant chemotherapy. In addition, DWI is promising as a noncontrast MRI alternative for breast cancer screening. Problems with suboptimal resolution and image quality have restricted the mainstream use of DWI for breast imaging, but these shortcomings are being addressed through several technologic advancements. In this review, we present an up-to-date assessment of the use of DWI for breast cancer imaging, including a summary of the clinical literature and recommendations for future use.
Collapse
Affiliation(s)
- Roberto Lo Gullo
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Savannah C Partridge
- Department of Radiology, University of Washington School of Medicine, University of Washington, Seattle, WA, USA 98109, USA
| | - Hee Jung Shin
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea
| | - Sunitha B Thakur
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Katja Pinker
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| |
Collapse
|
4
|
Adrada BE, Moseley TW, Kapoor MM, Scoggins ME, Patel MM, Perez F, Nia ES, Khazai L, Arribas E, Rauch GM, Guirguis MS. Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment. Radiographics 2023; 43:e230034. [PMID: 37792593 PMCID: PMC10560981 DOI: 10.1148/rg.230034] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 05/09/2023] [Accepted: 06/01/2023] [Indexed: 10/06/2023]
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive group of tumors that are defined by the absence of estrogen and progesterone receptors and lack of ERBB2 (formerly HER2 or HER2/neu) overexpression. TNBC accounts for 8%-13% of breast cancers. In addition, it accounts for a higher proportion of breast cancers in younger women compared with those in older women, and it disproportionately affects non-Hispanic Black women. TNBC has high metastatic potential, and the risk of recurrence is highest during the 5 years after it is diagnosed. TNBC exhibits benign morphologic imaging features more frequently than do other breast cancer subtypes. Mammography can be suboptimal for early detection of TNBC owing to factors that include the fast growth of this cancer, increased mammographic density in young women, and lack of the typical features of malignancy at imaging. US is superior to mammography for TNBC detection, but benign-appearing features can lead to misdiagnosis. Breast MRI is the most sensitive modality for TNBC detection. Most cases of TNBC are treated with neoadjuvant chemotherapy, followed by surgery and radiation. MRI is the modality of choice for evaluating the response to neoadjuvant chemotherapy. Survival rates for individuals with TNBC are lower than those for persons with hormone receptor-positive and human epidermal growth factor receptor 2-positive cancers. The 5-year survival rates for patients with localized, regional, and distant disease at diagnosis are 91.3%, 65.8%, and 12.0%, respectively. The early success of immunotherapy has raised hope regarding the development of personalized strategies to treat TNBC. Imaging and tumor biomarkers are likely to play a crucial role in the prediction of TNBC treatment response and TNBC patient survival in the future. ©RSNA, 2023 Quiz questions for this article are available in the supplemental material.
Collapse
Affiliation(s)
- Beatriz E. Adrada
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Tanya W. Moseley
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Megha M. Kapoor
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Marion E. Scoggins
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Miral M. Patel
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Frances Perez
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Emily S. Nia
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Laila Khazai
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Elsa Arribas
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Gaiane M. Rauch
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| | - Mary S. Guirguis
- From the Departments of Breast Imaging (B.E.A., T.W.M., M.M.K.,
M.E.S., M.M.P., F.P., E.S.N., E.A., G.M.R., M.S.G.), Breast Surgical Oncology
(T.W.M.), Pathology-Anatomical (L.K.), and Abdominal Imaging (G.M.R.), The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1350,
Houston, TX 77030
| |
Collapse
|
5
|
Jannusch K, Lindemann ME, Bruckmann NM, Morawitz J, Dietzel F, Pomykala KL, Herrmann K, Bittner AK, Hoffmann O, Mohrmann S, Umutlu L, Antoch G, Quick HH, Kirchner J. Towards a fast PET/MRI protocol for breast cancer imaging: maintaining diagnostic confidence while reducing PET and MRI acquisition times. Eur Radiol 2023; 33:6179-6188. [PMID: 37045980 PMCID: PMC10415438 DOI: 10.1007/s00330-023-09580-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2022] [Revised: 02/06/2023] [Accepted: 02/14/2023] [Indexed: 04/14/2023]
Abstract
OBJECTIVES To investigate the diagnostic feasibility of a shortened breast PET/MRI protocol in breast cancer patients. METHODS Altogether 90 women with newly diagnosed T1tumor-staged (T1ts) and T2tumor-staged (T2ts) breast cancer were included in this retrospective study. All underwent a dedicated comprehensive breast [18F]FDG-PET/MRI. List-mode PET data were retrospectively reconstructed with 20, 15, 10, and 5 min for each patient to simulate the effect of reduced PET acquisition times. The SUVmax/mean of all malign breast lesions was measured. Furthermore, breast PET data reconstructions were analyzed regarding image quality, lesion detectability, signal-to-noise ratio (SNR), and image noise (IN). The simultaneously acquired comprehensive MRI protocol was then shortened by retrospectively removing sequences from the protocol. Differences in malignant breast lesion detectability between the original and the fast breast MRI protocol were evaluated lesion-based. The 20-min PET reconstructions and the original MRI protocol served as reference. RESULTS In all PET reconstructions, 127 congruent breast lesions could be detected. Group comparison and T1ts vs. T2ts subgroup comparison revealed no significant difference of subjective image quality between 20, 15, 10, and 5 min acquisition times. SNR of qualitative image evaluation revealed no significant difference between different PET acquisition times. A slight but significant increase of IN with decreasing PET acquisition times could be detected. Lesion SUVmax group comparison between all PET acquisition times revealed no significant differences. Lesion-based evaluation revealed no significant difference in breast lesion detectability between original and fast breast MRI protocols. CONCLUSIONS Breast [18F]FDG-PET/MRI protocols can be shortened from 20 to below 10 min without losing essential diagnostic information. KEY POINTS • A highly accurate breast cancer evaluation is possible by the shortened breast [18F]FDG-PET/MRI examination protocol. • Significant time saving at breast [18F]FDG-PET/MRI protocol could increase patient satisfaction and patient throughput for breast cancer patients at PET/MRI.
Collapse
Affiliation(s)
- Kai Jannusch
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstrasse 5, D-40225, Dusseldorf, Germany.
| | - Maike E Lindemann
- High-Field and Hybrid MR Imaging, University Hospital Essen, University Duisburg-Essen, D-45147, Essen, Germany
| | - Nils Martin Bruckmann
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstrasse 5, D-40225, Dusseldorf, Germany
| | - Janna Morawitz
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstrasse 5, D-40225, Dusseldorf, Germany
| | - Frederic Dietzel
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstrasse 5, D-40225, Dusseldorf, Germany
| | - Kelsey L Pomykala
- Department for Artificial Intelligence in Medicine, University Hospital Essen, University of Duisburg-Essen, D-45131, Essen, Germany
| | - Ken Herrmann
- Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, D-45147, Essen, Germany
| | - Ann-Kathrin Bittner
- Department Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, D-45147, Essen, Germany
| | - Oliver Hoffmann
- Department Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, D-45147, Essen, Germany
| | - Svjetlana Mohrmann
- Department of Gynecology, Medical Faculty, University Dusseldorf, D-40225, Dusseldorf, Germany
| | - Lale Umutlu
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, D-45147, Essen, Germany
| | - Gerald Antoch
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstrasse 5, D-40225, Dusseldorf, Germany
| | - Harald H Quick
- High-Field and Hybrid MR Imaging, University Hospital Essen, University Duisburg-Essen, D-45147, Essen, Germany
- Erwin L. Hahn Institute for Magnetic Resonance Imaging, University Duisburg-Essen, D-45141, Essen, Germany
| | - Julian Kirchner
- Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, Moorenstrasse 5, D-40225, Dusseldorf, Germany
| |
Collapse
|
6
|
Hayward JH, Linden OE, Lewin AA, Weinstein SP, Bachorik AE, Balija TM, Kuzmiak CM, Paulis LV, Salkowski LR, Sanford MF, Scheel JR, Sharpe RE, Small W, Ulaner GA, Slanetz PJ. ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer: 2022 Update. J Am Coll Radiol 2023; 20:S125-S145. [PMID: 37236739 DOI: 10.1016/j.jacr.2023.02.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Accepted: 02/27/2023] [Indexed: 05/28/2023]
Abstract
Imaging plays a vital role in managing patients undergoing neoadjuvant chemotherapy, as treatment decisions rely heavily on accurate assessment of response to therapy. This document provides evidence-based guidelines for imaging breast cancer before, during, and after initiation of neoadjuvant chemotherapy. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
Collapse
Affiliation(s)
| | - Olivia E Linden
- Research Author, University of California, San Francisco, San Francisco, California
| | - Alana A Lewin
- Panel Chair, New York University Grossman School of Medicine, New York, New York
| | - Susan P Weinstein
- Panel Vice-Chair, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania
| | | | - Tara M Balija
- Hackensack University Medical Center, Hackensack, New Jersey; American College of Surgeons
| | - Cherie M Kuzmiak
- University of North Carolina Hospital, Chapel Hill, North Carolina
| | | | - Lonie R Salkowski
- University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin
| | | | | | | | - William Small
- Loyola University Chicago, Stritch School of Medicine, Department of Radiation Oncology, Cardinal Bernardin Cancer Center, Maywood, Illinois
| | - Gary A Ulaner
- Hoag Family Cancer Institute, Newport Beach, California, and University of Southern California, Los Angeles, California; Commission on Nuclear Medicine and Molecular Imaging
| | - Priscilla J Slanetz
- Specialty Chair, Boston University School of Medicine, Boston, Massachusetts
| |
Collapse
|
7
|
Yao FF, Zhang Y. A review of quantitative diffusion-weighted MR imaging for breast cancer: Towards noninvasive biomarker. Clin Imaging 2023; 98:36-58. [PMID: 36996598 DOI: 10.1016/j.clinimag.2023.03.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Revised: 03/03/2023] [Accepted: 03/21/2023] [Indexed: 04/01/2023]
Abstract
Quantitative diffusion-weighted imaging (DWI) is an important adjunct to conventional breast MRI and shows promise as a noninvasive biomarker of breast cancer in multiple clinical scenarios, from the discrimination of benign and malignant lesions, prediction, and evaluation of treatment response to a prognostic assessment of breast cancer. Various quantitative parameters are derived from different DWI models based on special prior knowledge and assumptions, have different meanings, and are easy to confuse. In this review, we describe the quantitative parameters derived from conventional and advanced DWI models commonly used in breast cancer and summarize the promising clinical applications of these quantitative parameters. Although promising, it is still challenging for these quantitative parameters to become clinically useful noninvasive biomarkers in breast cancer, as multiple factors may result in variations in quantitative parameter measurements. Finally, we briefly describe some considerations regarding the factors that cause variations.
Collapse
Affiliation(s)
- Fei-Fei Yao
- Department of MRI in the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
| | - Yan Zhang
- Department of MRI in the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
| |
Collapse
|
8
|
Surgical Planning after Neoadjuvant Treatment in Breast Cancer: A Multimodality Imaging-Based Approach Focused on MRI. Cancers (Basel) 2023; 15:cancers15051439. [PMID: 36900231 PMCID: PMC10001061 DOI: 10.3390/cancers15051439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Revised: 02/19/2023] [Accepted: 02/21/2023] [Indexed: 03/12/2023] Open
Abstract
Neoadjuvant chemotherapy (NACT) today represents a cornerstone in the treatment of locally advanced breast cancer and highly chemo-sensitive tumors at early stages, increasing the possibilities of performing more conservative treatments and improving long term outcomes. Imaging has a fundamental role in the staging and prediction of the response to NACT, thus aiding surgical planning and avoiding overtreatment. In this review, we first examine and compare the role of conventional and advanced imaging techniques in preoperative T Staging after NACT and in the evaluation of lymph node involvement. In the second part, we analyze the different surgical approaches, discussing the role of axillary surgery, as well as the possibility of non-operative management after-NACT, which has been the subject of recent trials. Finally, we focus on emerging techniques that will change the diagnostic assessment of breast cancer in the near future.
Collapse
|
9
|
Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study. Cancer Imaging 2022; 22:68. [PMID: 36494872 PMCID: PMC9733082 DOI: 10.1186/s40644-022-00501-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Accepted: 10/25/2022] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Magnetic resonance imaging (MRI) can be used to diagnose breast cancer. Diffusion weighted imaging (DWI) and the apparent diffusion coefficient (ADC) can reflect tumor microstructure in a non-invasive manner. The correct prediction of response of neoadjuvant chemotherapy (NAC) is crucial for clinical routine. Our aim was to compare ADC values between patients with pathological complete response (pCR) and non-responders based upon a multi-center design to improve the correct patient selection, which patient would more benefit from NAC and which patient would not. METHODS For this study, data from 4 centers (from Japan, Brazil, Spain and United Kingdom) were retrospectively acquired. The time period was overall 2003-2019. The patient sample comprises 250 patients (all female; median age, 50.5). In every case, pretreatment breast MRI with DWI was performed. pCR was assessed by experienced pathologists in every center using the surgical specimen in the clinical routine work up. pCR was defined as no residual invasive disease in either breast or axillary lymph nodes after NAC. ADC values between the group with pCR and those with no pCR were compared using the Mann-Whitney U test (two-group comparisons). Univariable and multivariabe logistic regression analysis was performed to predict pCR status. RESULTS Overall, 83 patients (33.2%) achieved pCR. The ADC values of the patient group with pCR were lower compared with patients without pCR (0.98 ± 0.23 × 10- 3 mm2/s versus 1.07 ± 0.24 × 10- 3 mm2/s, p = 0.02). The ADC value achieved an odds ratio of 4.65 (95% CI 1.40-15.49) in univariable analysis and of 3.0 (95% CI 0.85-10.63) in multivariable analysis (overall sample) to be associated with pCR status. The odds ratios differed in the subgroup analyses in accordance with the molecular subtype. CONCLUSIONS The pretreatment ADC-value is associated with pathological complete response after NAC in breast cancer patients. This could aid in clinical routine to reduce treatment toxicity for patients, who would not benefit from NAC. However, this must be tested in further studies, as the overlap of the ADC values in both groups is too high for clinical prediction.
Collapse
|
10
|
Panico C, Ferrara F, Woitek R, D’Angelo A, Di Paola V, Bufi E, Conti M, Palma S, Cicero SL, Cimino G, Belli P, Manfredi R. Staging Breast Cancer with MRI, the T. A Key Role in the Neoadjuvant Setting. Cancers (Basel) 2022; 14:cancers14235786. [PMID: 36497265 PMCID: PMC9739275 DOI: 10.3390/cancers14235786] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 11/15/2022] [Accepted: 11/17/2022] [Indexed: 11/27/2022] Open
Abstract
Breast cancer (BC) is the most common cancer among women worldwide. Neoadjuvant chemotherapy (NACT) indications have expanded from inoperable locally advanced to early-stage breast cancer. Achieving a pathological complete response (pCR) has been proven to be an excellent prognostic marker leading to better disease-free survival (DFS) and overall survival (OS). Although diagnostic accuracy of MRI has been shown repeatedly to be superior to conventional methods in assessing the extent of breast disease there are still controversies regarding the indication of MRI in this setting. We intended to review the complex literature concerning the tumor size in staging, response and surgical planning in patients with early breast cancer receiving NACT, in order to clarify the role of MRI. Morphological and functional MRI techniques are making headway in the assessment of the tumor size in the staging, residual tumor assessment and prediction of response. Radiomics and radiogenomics MRI applications in the setting of the prediction of response to NACT in breast cancer are continuously increasing. Tailored therapy strategies allow considerations of treatment de-escalation in excellent responders and avoiding or at least postponing breast surgery in selected patients.
Collapse
Affiliation(s)
- Camilla Panico
- Department of Bioimaging, Radiation Oncology and Hematology, UOC of Radiologia, Fondazione Policlinico Universitario A. Gemelli IRCSS, Largo A. Gemelli 8, 00168 Rome, Italy
- Correspondence:
| | - Francesca Ferrara
- Institute of Radiology, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy
| | - Ramona Woitek
- Medical Image Analysis and AI (MIAAI), Danube Private University, 3500 Krems, Austria
- Department of Radiology, University of Cambridge, Cambridge CB2 0QQ, UK
- Cancer Research UK Cambridge Centre, Cambridge CB2 0RE, UK
| | - Anna D’Angelo
- Department of Bioimaging, Radiation Oncology and Hematology, UOC of Radiologia, Fondazione Policlinico Universitario A. Gemelli IRCSS, Largo A. Gemelli 8, 00168 Rome, Italy
| | - Valerio Di Paola
- Department of Bioimaging, Radiation Oncology and Hematology, UOC of Radiologia, Fondazione Policlinico Universitario A. Gemelli IRCSS, Largo A. Gemelli 8, 00168 Rome, Italy
| | - Enida Bufi
- Department of Bioimaging, Radiation Oncology and Hematology, UOC of Radiologia, Fondazione Policlinico Universitario A. Gemelli IRCSS, Largo A. Gemelli 8, 00168 Rome, Italy
| | - Marco Conti
- Department of Bioimaging, Radiation Oncology and Hematology, UOC of Radiologia, Fondazione Policlinico Universitario A. Gemelli IRCSS, Largo A. Gemelli 8, 00168 Rome, Italy
| | - Simone Palma
- Institute of Radiology, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy
| | - Stefano Lo Cicero
- Institute of Radiology, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy
| | - Giovanni Cimino
- Institute of Radiology, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy
| | - Paolo Belli
- Department of Bioimaging, Radiation Oncology and Hematology, UOC of Radiologia, Fondazione Policlinico Universitario A. Gemelli IRCSS, Largo A. Gemelli 8, 00168 Rome, Italy
- Institute of Radiology, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy
| | - Riccardo Manfredi
- Department of Bioimaging, Radiation Oncology and Hematology, UOC of Radiologia, Fondazione Policlinico Universitario A. Gemelli IRCSS, Largo A. Gemelli 8, 00168 Rome, Italy
- Institute of Radiology, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168 Rome, Italy
| |
Collapse
|
11
|
Lo Gullo R, Sevilimedu V, Baltzer P, Le Bihan D, Camps-Herrero J, Clauser P, Gilbert FJ, Iima M, Mann RM, Partridge SC, Patterson A, Sigmund EE, Thakur S, Thibault FE, Martincich L, Pinker K. A survey by the European Society of Breast Imaging on the implementation of breast diffusion-weighted imaging in clinical practice. Eur Radiol 2022; 32:6588-6597. [PMID: 35507050 PMCID: PMC9064723 DOI: 10.1007/s00330-022-08833-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 04/19/2022] [Accepted: 04/21/2022] [Indexed: 11/20/2022]
Abstract
OBJECTIVES To perform a survey among all European Society of Breast Imaging (EUSOBI) radiologist members to gather representative data regarding the clinical use of breast DWI. METHODS An online questionnaire was developed by two board-certified radiologists, reviewed by the EUSOBI board and committees, and finally distributed among EUSOBI active and associated (not based in Europe) radiologist members. The questionnaire included 20 questions pertaining to technical preferences (acquisition time, magnet strength, breast coils, number of b values), clinical indications, imaging evaluation, and reporting. Data were analyzed using descriptive statistics, the Chi-square test of independence, and Fisher's exact test. RESULTS Of 1411 EUSOBI radiologist members, 275/1411 (19.5%) responded. Most (222/275, 81%) reported using DWI as part of their routine protocol. Common indications for DWI include lesion characterization (using an ADC threshold of 1.2-1.3 × 10-3 mm2/s) and prediction of response to chemotherapy. Members most commonly acquire two separate b values (114/217, 53%), with b value = 800 s/mm2 being the preferred value for appraisal among those acquiring more than two b values (71/171, 42%). Most did not use synthetic b values (169/217, 78%). While most mention hindered diffusion in the MRI report (161/213, 76%), only 142/217 (57%) report ADC values. CONCLUSION The utilization of DWI in clinical practice among EUSOBI radiologists who responded to the survey is generally in line with international recommendations, with the main application being the differentiation of benign and malignant enhancing lesions, treatment response assessment, and prediction of response to chemotherapy. Report integration of qualitative and quantitative DWI data is not uniform. KEY POINTS • Clinical performance of breast DWI is in good agreement with the current recommendations of the EUSOBI International Breast DWI working group. • Breast DWI applications in clinical practice include the differentiation of benign and malignant enhancing, treatment response assessment, and prediction of response to chemotherapy. • Report integration of DWI results is not uniform.
Collapse
Affiliation(s)
- Roberto Lo Gullo
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, USA
| | - Varadan Sevilimedu
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Ave, NY, New York, 10017, USA
| | - Pascal Baltzer
- Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Structural Preclinical Imaging, Medical University of Vienna/Vienna General Hospital, Wien, Austria
| | - Denis Le Bihan
- NeuroSpin/Joliot, CEA-Saclay Center, Paris-Saclay University, Gif-sur-Yvette, France
- Human Brain Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan
- National Institute for Physiological Sciences, Okazaki, Japan
| | | | - Paola Clauser
- Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Structural Preclinical Imaging, Medical University of Vienna/Vienna General Hospital, Wien, Austria
| | - Fiona J Gilbert
- Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Mami Iima
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| | - Ritse M Mann
- Department of Diagnostic Imaging, Radboud University Medical Centre, Nijmegen, Netherlands
- Department of Radiology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Savannah C Partridge
- Department of Radiology, University of Washington School of Medicine, Seattle, WA, USA
| | - Andrew Patterson
- Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Eric E Sigmund
- Department of Radiology, NYU Langone Health, 6, 60 1st Avenue, New York, NY, 10016, USA
| | - Sunitha Thakur
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, USA
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, USA
| | - Fabienne E Thibault
- Department of Medical Imaging, Institut Curie, 26 Rue d'Ulm, F-75005, Paris, France
| | - Laura Martincich
- Unit of Radiodiagnostics, Ospedale Cardinal G. Massaia -ASL AT, Via Conte Verde 125, 14100, Asti, Italy
| | - Katja Pinker
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY, 10065, USA.
- Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Structural Preclinical Imaging, Medical University of Vienna/Vienna General Hospital, Wien, Austria.
| |
Collapse
|
12
|
Mendez AM, Fang LK, Meriwether CH, Batasin SJ, Loubrie S, Rodríguez-Soto AE, Rakow-Penner RA. Diffusion Breast MRI: Current Standard and Emerging Techniques. Front Oncol 2022; 12:844790. [PMID: 35880168 PMCID: PMC9307963 DOI: 10.3389/fonc.2022.844790] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Accepted: 05/11/2022] [Indexed: 11/13/2022] Open
Abstract
The role of diffusion weighted imaging (DWI) as a biomarker has been the subject of active investigation in the field of breast radiology. By quantifying the random motion of water within a voxel of tissue, DWI provides indirect metrics that reveal cellularity and architectural features. Studies show that data obtained from DWI may provide information related to the characterization, prognosis, and treatment response of breast cancer. The incorporation of DWI in breast imaging demonstrates its potential to serve as a non-invasive tool to help guide diagnosis and treatment. In this review, current technical literature of diffusion-weighted breast imaging will be discussed, in addition to clinical applications, advanced techniques, and emerging use in the field of radiomics.
Collapse
Affiliation(s)
- Ashley M. Mendez
- Department of Radiology, University of California San Diego, La Jolla, CA, United States
| | - Lauren K. Fang
- Department of Radiology, University of California San Diego, La Jolla, CA, United States
| | - Claire H. Meriwether
- Department of Radiology, University of California San Diego, La Jolla, CA, United States
| | - Summer J. Batasin
- Department of Radiology, University of California San Diego, La Jolla, CA, United States
| | - Stéphane Loubrie
- Department of Radiology, University of California San Diego, La Jolla, CA, United States
| | - Ana E. Rodríguez-Soto
- Department of Radiology, University of California San Diego, La Jolla, CA, United States
| | - Rebecca A. Rakow-Penner
- Department of Radiology, University of California San Diego, La Jolla, CA, United States,Department of Bioengineering, University of California San Diego, La Jolla, CA, United States,*Correspondence: Rebecca A. Rakow-Penner,
| |
Collapse
|
13
|
Galati F, Rizzo V, Trimboli RM, Kripa E, Maroncelli R, Pediconi F. MRI as a biomarker for breast cancer diagnosis and prognosis. BJR Open 2022; 4:20220002. [PMID: 36105423 PMCID: PMC9459861 DOI: 10.1259/bjro.20220002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 05/01/2022] [Accepted: 05/04/2022] [Indexed: 11/05/2022] Open
Abstract
Breast cancer (BC) is the most frequently diagnosed female invasive cancer in Western countries and the leading cause of cancer-related death worldwide. Nowadays, tumor heterogeneity is a well-known characteristic of BC, since it includes several nosological entities characterized by different morphologic features, clinical course and response to treatment. Thus, with the spread of molecular biology technologies and the growing knowledge of the biological processes underlying the development of BC, the importance of imaging biomarkers as non-invasive information about tissue hallmarks has progressively grown. To date, breast magnetic resonance imaging (MRI) is considered indispensable in breast imaging practice, with widely recognized indications such as BC screening in females at increased risk, locoregional staging and neoadjuvant therapy (NAT) monitoring. Moreover, breast MRI is increasingly used to assess not only the morphologic features of the pathological process but also to characterize individual phenotypes for targeted therapies, building on developments in genomics and molecular biology features. The aim of this review is to explore the role of breast multiparametric MRI in providing imaging biomarkers, leading to an improved differentiation of benign and malignant breast lesions and to a customized management of BC patients in monitoring and predicting response to treatment. Finally, we discuss how breast MRI biomarkers offer one of the most fertile ground for artificial intelligence (AI) applications. In the era of personalized medicine, with the development of omics-technologies, machine learning and big data, the role of imaging biomarkers is embracing new opportunities for BC diagnosis and treatment.
Collapse
Affiliation(s)
- Francesca Galati
- Department of Radiological, Oncological and Pathological Sciences, “Sapienza” - University of Rome, Viale Regina Elena, Rome, Italy
| | - Veronica Rizzo
- Department of Radiological, Oncological and Pathological Sciences, “Sapienza” - University of Rome, Viale Regina Elena, Rome, Italy
| | | | - Endi Kripa
- Department of Radiological, Oncological and Pathological Sciences, “Sapienza” - University of Rome, Viale Regina Elena, Rome, Italy
| | - Roberto Maroncelli
- Department of Radiological, Oncological and Pathological Sciences, “Sapienza” - University of Rome, Viale Regina Elena, Rome, Italy
| | - Federica Pediconi
- Department of Radiological, Oncological and Pathological Sciences, “Sapienza” - University of Rome, Viale Regina Elena, Rome, Italy
| |
Collapse
|
14
|
Kong X, Zhang Q, Wu X, Zou T, Duan J, Song S, Nie J, Tao C, Tang M, Wang M, Zou J, Xie Y, Li Z, Li Z. Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Front Oncol 2022; 12:816297. [PMID: 35669440 PMCID: PMC9163342 DOI: 10.3389/fonc.2022.816297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Accepted: 03/29/2022] [Indexed: 11/13/2022] Open
Abstract
Neoadjuvant chemotherapy (NAC) is increasingly widely used in breast cancer treatment, and accurate evaluation of its response provides essential information for treatment and prognosis. Thus, the imaging tools used to quantify the disease response are critical in evaluating and managing patients treated with NAC. We discussed the recent progress, advantages, and disadvantages of common imaging methods in assessing the efficacy of NAC for breast cancer.
Collapse
Affiliation(s)
- Xianshu Kong
- Third Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Qian Zhang
- Third Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Xuemei Wu
- Third Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Tianning Zou
- Third Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Jiajun Duan
- Third Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Shujie Song
- Department of Pathology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Jianyun Nie
- Third Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Chu Tao
- Third Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Mi Tang
- Department of Pathology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Maohua Wang
- First Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Jieya Zou
- Third Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Yu Xie
- Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
| | - Zhenhui Li
- Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
- *Correspondence: Zhen Li, ; Zhenhui Li,
| | - Zhen Li
- Third Department of the Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China
- *Correspondence: Zhen Li, ; Zhenhui Li,
| |
Collapse
|
15
|
Mori N, Inoue C, Tamura H, Nagasaka T, Ren H, Sato S, Mori Y, Miyashita M, Mugikura S, Takase K. Apparent diffusion coefficient and intravoxel incoherent motion-diffusion kurtosis model parameters in invasive breast cancer: Correlation with the histological parameters of whole-slide imaging. Magn Reson Imaging 2022; 90:53-60. [DOI: 10.1016/j.mri.2022.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 03/04/2022] [Accepted: 04/12/2022] [Indexed: 01/18/2023]
|
16
|
Kazama T, Takahara T, Hashimoto J. Breast Cancer Subtypes and Quantitative Magnetic Resonance Imaging: A Systemic Review. Life (Basel) 2022; 12:life12040490. [PMID: 35454981 PMCID: PMC9028183 DOI: 10.3390/life12040490] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Revised: 02/20/2022] [Accepted: 03/08/2022] [Indexed: 12/12/2022] Open
Abstract
Magnetic resonance imaging (MRI) is the most sensitive imaging modality for breast cancer detection. This systematic review investigated the role of quantitative MRI features in classifying molecular subtypes of breast cancer. We performed a literature search of articles published on the application of quantitative MRI features in invasive breast cancer molecular subtype classification in PubMed from 1 January 2002 to 30 September 2021. Of the 1275 studies identified, 106 studies with a total of 12,989 patients fulfilled the inclusion criteria. Bias was assessed based using the Quality Assessment of Diagnostic Studies. All studies were case-controlled and research-based. Most studies assessed quantitative MRI features using dynamic contrast-enhanced (DCE) kinetic features and apparent diffusion coefficient (ADC) values. We present a summary of the quantitative MRI features and their correlations with breast cancer subtypes. In DCE studies, conflicting results have been reported; therefore, we performed a meta-analysis. Significant differences in the time intensity curve patterns were observed between receptor statuses. In 10 studies, including a total of 1276 lesions, the pooled difference in proportions of type Ⅲ curves (wash-out) between oestrogen receptor-positive and -negative cancers was not significant (95% confidence interval (CI): [−0.10, 0.03]). In nine studies, including a total of 1070 lesions, the pooled difference in proportions of type 3 curves between human epidermal growth factor receptor 2-positive and -negative cancers was significant (95% CI: [0.01, 0.14]). In six studies including a total of 622 lesions, the pooled difference in proportions of type 3 curves between the high and low Ki-67 groups was significant (95% CI: [0.17, 0.44]). However, the type 3 curve itself is a nonspecific finding in breast cancer. Many studies have examined the relationship between mean ADC and breast cancer subtypes; however, the ADC values overlapped significantly between subtypes. The heterogeneity of ADC using kurtosis or difference, diffusion tensor imaging parameters, and relaxation time was reported recently with promising results; however, current evidence is limited, and further studies are required to explore these potential applications.
Collapse
Affiliation(s)
- Toshiki Kazama
- Department of Diagnostic Radiology, Tokai University School of Medicine, Isehara 259-1193, Japan;
- Correspondence: ; Tel.: +81-463-93-1121
| | - Taro Takahara
- Department of Biomedical Engineering, Tokai University School of Engineering, Hiratsuka 259-1207, Japan;
| | - Jun Hashimoto
- Department of Diagnostic Radiology, Tokai University School of Medicine, Isehara 259-1193, Japan;
| |
Collapse
|
17
|
Magnetic Resonance Imaging (MRI) and MR Spectroscopic Methods in Understanding Breast Cancer Biology and Metabolism. Metabolites 2022; 12:metabo12040295. [PMID: 35448482 PMCID: PMC9030399 DOI: 10.3390/metabo12040295] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 03/22/2022] [Accepted: 03/23/2022] [Indexed: 02/01/2023] Open
Abstract
A common malignancy that affects women is breast cancer. It is the second leading cause of cancer-related death among women. Metabolic reprogramming occurs during cancer growth, invasion, and metastases. Functional magnetic resonance (MR) methods comprising an array of techniques have shown potential for illustrating physiological and molecular processes changes before anatomical manifestations on conventional MR imaging. Among these, in vivo proton (1H) MR spectroscopy (MRS) is widely used for differentiating breast malignancy from benign diseases by measuring elevated choline-containing compounds. Further, the use of hyperpolarized 13C and 31P MRS enhanced the understanding of glucose and phospholipid metabolism. The metabolic profiling of an array of biological specimens (intact tissues, tissue extracts, and various biofluids such as blood, urine, nipple aspirates, and fine needle aspirates) can also be investigated through in vitro high-resolution NMR spectroscopy and high-resolution magic angle spectroscopy (HRMAS). Such studies can provide information on more metabolites than what is seen by in vivo MRS, thus providing a deeper insight into cancer biology and metabolism. The analysis of a large number of NMR spectral data sets through multivariate statistical methods classified the tumor sub-types. It showed enormous potential in the development of new therapeutic approaches. Recently, multiparametric MRI approaches were found to be helpful in elucidating the pathophysiology of cancer by quantifying structural, vasculature, diffusion, perfusion, and metabolic abnormalities in vivo. This review focuses on the applications of NMR, MRS, and MRI methods in understanding breast cancer biology and in the diagnosis and therapeutic monitoring of breast cancer.
Collapse
|
18
|
Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial. Tomography 2022; 8:701-717. [PMID: 35314635 PMCID: PMC8938828 DOI: 10.3390/tomography8020058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Revised: 02/15/2022] [Accepted: 02/25/2022] [Indexed: 11/16/2022] Open
Abstract
In diffusion-weighted MRI (DW-MRI), choice of b-value influences apparent diffusion coefficient (ADC) values by probing different aspects of the tissue microenvironment. As a secondary analysis of the multicenter ECOG-ACRIN A6698 trial, the purpose of this study was to investigate the impact of alternate b-value combinations on the performance and repeatability of tumor ADC as a predictive marker of breast cancer treatment response. The final analysis included 210 women who underwent standardized 4-b-value DW-MRI (b = 0/100/600/800 s/mm2) at multiple timepoints during neoadjuvant chemotherapy treatment and a subset (n = 71) who underwent test−retest scans. Centralized tumor ADC and perfusion fraction (fp) measures were performed using variable b-value combinations. Prediction of pathologic complete response (pCR) based on the mid-treatment/12-week percent change in each metric was estimated by area under the receiver operating characteristic curve (AUC). Repeatability was estimated by within-subject coefficient of variation (wCV). Results show that two-b-value ADC calculations provided non-inferior predictive value to four-b-value ADC calculations overall (AUCs = 0.60−0.61 versus AUC = 0.60) and for HR+/HER2− cancers where ADC was most predictive (AUCs = 0.75−0.78 versus AUC = 0.76), p < 0.05. Using two b-values (0/600 or 0/800 s/mm2) did not reduce ADC repeatability over the four-b-value calculation (wCVs = 4.9−5.2% versus 5.4%). The alternate metrics ADCfast (b ≤ 100 s/mm2), ADCslow (b ≥ 100 s/mm2), and fp did not improve predictive performance (AUCs = 0.54−0.60, p = 0.08−0.81), and ADCfast and fp demonstrated the lowest repeatability (wCVs = 6.71% and 12.4%, respectively). In conclusion, breast tumor ADC calculated using a simple two-b-value approach can provide comparable predictive value and repeatability to full four-b-value measurements as a marker of treatment response.
Collapse
|
19
|
Geng X, Zhang D, Suo S, Chen J, Cheng F, Zhang K, Zhang Q, Li L, Lu Y, Hua J, Zhuang Z. Using the apparent diffusion coefficient histogram analysis to predict response to neoadjuvant chemotherapy in patients with breast cancer: comparison among three region of interest selection methods. ANNALS OF TRANSLATIONAL MEDICINE 2022; 10:323. [PMID: 35433990 PMCID: PMC9011214 DOI: 10.21037/atm-22-1078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 03/18/2022] [Indexed: 11/06/2022]
Abstract
Background The apparent diffusion coefficient (ADC) value using histogram analysis is helpful to predict responses to neoadjuvant chemotherapy (NAC) in breast cancer. However, the measurement method has not reached a consensus. This study was to assess the diagnostic performance of the ADC histogram analysis at predicting patient response prior to NAC in breast cancer patients using different region of interest (ROI) selection methods. Methods A total of 75 patients who underwent diffusion weighted imaging (DWI) prior to NAC were retrospectively enrolled from February 2017 to December 2019. Images were measured using small 2-dimensional (2D) ROI, large 2D ROI, and volume ROI methods. The measurement time and ROI size were recorded. Histopathologic responses were acquired using the Miller-Payne grading system after surgery. The inter- and intra-observer repeatability was analyzed and the ADC histogram values from the three ROI methods were compared. The efficacy of each method at predicting patient response prior to NAC was assessed using the area under the receiver operating characteristic curve (AUC) for the whole study population and subgroups according to molecular subtype. Results Among the 75 enrolled patients, 26 (34.67%) were responsive to NAC therapy. The ADC histogram values were significantly different among the three ROI methods (P≤0.038). Inter- and intra-observer repeatability of the large 2D ROI method and the volume ROI method was generally greater than that observed with the 2D ROI method. The 10% ADC value of the large 2D ROI method showed the greatest AUC (0.701) in the whole study population and in the luminal subgroup (AUC 0.804). The volume ROI method required significantly more time than the other two ROI methods (P<0.001). Conclusions The small 2D ROI method is not appropriate for predicting response prior to NAC in breast cancer patients due to the poor repeatability. When choosing the ROI method and the histogram parameters for predicting response prior to NAC in breast cancer patients using ADC-derived histogram analysis, 10% of the large 2D ROI method is recommended, especially in luminal A subtype patients.
Collapse
Affiliation(s)
- Xiaochuan Geng
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Dandan Zhang
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Shiteng Suo
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jie Chen
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Fang Cheng
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Kebei Zhang
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Qing Zhang
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Lan Li
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yang Lu
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jia Hua
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Zhiguo Zhuang
- Department of Radiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
20
|
Li G, Li L, Li Y, Qian Z, Wu F, He Y, Jiang H, Li R, Wang D, Zhai Y, Wang Z, Jiang T, Zhang J, Zhang W. An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas. Brain 2022; 145:1151-1161. [PMID: 35136934 PMCID: PMC9050568 DOI: 10.1093/brain/awab340] [Citation(s) in RCA: 79] [Impact Index Per Article: 39.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 04/15/2021] [Accepted: 08/18/2021] [Indexed: 01/08/2023] Open
Abstract
Preoperative MRI is one of the most important clinical results for the diagnosis and treatment of glioma patients. The objective of this study was to construct a stable and validatable preoperative T2-weighted MRI-based radiomics model for predicting the survival of gliomas. A total of 652 glioma patients across three independent cohorts were covered in this study including their preoperative T2-weighted MRI images, RNA-seq and clinical data. Radiomic features (1731) were extracted from preoperative T2-weighted MRI images of 167 gliomas (discovery cohort) collected from Beijing Tiantan Hospital and then used to develop a radiomics prediction model through a machine learning-based method. The performance of the radiomics prediction model was validated in two independent cohorts including 261 gliomas from the The Cancer Genomae Atlas database (external validation cohort) and 224 gliomas collected in the prospective study from Beijing Tiantan Hospital (prospective validation cohort). RNA-seq data of gliomas from discovery and external validation cohorts were applied to establish the relationship between biological function and the key radiomics features, which were further validated by single-cell sequencing and immunohistochemical staining. The 14 radiomic features-based prediction model was constructed from preoperative T2-weighted MRI images in the discovery cohort, and showed highly robust predictive power for overall survival of gliomas in external and prospective validation cohorts. The radiomic features in the prediction model were associated with immune response, especially tumour macrophage infiltration. The preoperative T2-weighted MRI radiomics prediction model can stably predict the survival of glioma patients and assist in preoperatively assessing the extent of macrophage infiltration in glioma tumours.
Collapse
Affiliation(s)
- Guanzhang Li
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
| | - Lin Li
- Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, School of Biological Science and Medical Engineering, Beihang University, Beijing, 100083, China
| | - Yiming Li
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
| | - Zenghui Qian
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
| | - Fan Wu
- Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China
| | - Yufei He
- Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, School of Biological Science and Medical Engineering, Beihang University, Beijing, 100083, China
| | - Haoyu Jiang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
| | - Renpeng Li
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
| | - Di Wang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
| | - You Zhai
- Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China
| | - Zhiliang Wang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
| | - Tao Jiang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.,Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.,Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing 100070, China.,China National Clinical Research Center for Neurological Diseases, Beijing 100070, China.,Chinese Glioma Genome Atlas Network and Asian Glioma Genome Atlas Network, Beijing, China
| | - Jing Zhang
- Laboratory for Biomechanics and Mechanobiology of Ministry of Education, Beijing Advanced Innovation Center for Biomedical Engineering, School of Engineering Medicine, School of Biological Science and Medical Engineering, Beihang University, Beijing, 100083, China
| | - Wei Zhang
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.,Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China.,China National Clinical Research Center for Neurological Diseases, Beijing 100070, China.,Chinese Glioma Genome Atlas Network and Asian Glioma Genome Atlas Network, Beijing, China
| |
Collapse
|
21
|
Zhang D, Geng X, Suo S, Zhuang Z, Gu Y, Hua J. The predictive value of DKI in breast cancer: Does tumour subtype affect pathological response evaluations? Magn Reson Imaging 2021; 85:28-34. [PMID: 34662700 DOI: 10.1016/j.mri.2021.10.013] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 07/25/2021] [Accepted: 10/12/2021] [Indexed: 12/18/2022]
Abstract
PURPOSE To explore the differences in quantitative parameters based on diffusion weighted imaging (DWI) and diffusion kurtosis imaging (DKI) between different immunohistochemical indicator statuses and their predictive value for neoadjuvant chemotherapy (NAC) among different phenotypes of breast cancer. METHODS Eighty-one breast cancer patients who underwent NAC were enrolled in this retrospective study. Correlations between diffusion parameters and immunohistochemical indicators were determined using Spearman's test, and receiver operating characteristic (ROC) curves were constructed to assess the apparent diffusion coefficient (ADC), mean diffusivity (MD), and mean kurtosis (MK) in predicting the pathologic complete response (PCR). RESULTS Correlations were observed between MK values and hormone receptor (HR) expression (oestrogen receptor (ER): r = 0.315 and progesterone receptor (PR): r = 0.268). The parameters ADC(0,1000), MK, and MD all showed correlations with Ki67 expression (r = 0.276, 0.316 and - 0.224, respectively). ER and Ki67 expression and the parameters MD and MK were significantly different between the PCR and non-PCR groups (AUC = 0.783, 0.688, 0.649 and 0.684, respectively). After splitting patients into subgroups, no significant differences were observed between the PCR and non-PCR groups with human epidermal growth factor receptor 2 (HER2) + and triple-negative (TN) breast cancer. However, we were surprised to find that ADC(0, 1000), MD, and MK were significantly different between different remission groups with HR+/HER2+ subtypes, and the AUCs of each parameter reached 0.794, 0.825, and 0.712, respectively. CONCLUSION MK was correlated with HR expression. ADC(0, 1000) and DKI were correlated with Ki67 expression. ADC(0, 1000) and the non-Gaussian diffusion model are suitable for predicting PCR in patients with HR+/HER2+ breast cancer before NAC.
Collapse
Affiliation(s)
- Dandan Zhang
- Department of Radiology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, No.270 Dongan Rd., Shanghai 200032, People's Republic of China
| | - Xiaochuan Geng
- Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160 Pujian Rd., Shanghai 200127, People's Republic of China; Department of Radiology, Renji Hospital South Campus, School of Medicine, Shanghai Jiao Tong University, No.2000 Jiangyue Rd., Shanghai 201112, People's Republic of China
| | - Shiteng Suo
- Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160 Pujian Rd., Shanghai 200127, People's Republic of China
| | - Zhiguo Zhuang
- Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160 Pujian Rd., Shanghai 200127, People's Republic of China
| | - Yajia Gu
- Department of Radiology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, No.270 Dongan Rd., Shanghai 200032, People's Republic of China.
| | - Jia Hua
- Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, No.160 Pujian Rd., Shanghai 200127, People's Republic of China.
| |
Collapse
|
22
|
Choi BB. Effectiveness of ADC Difference Value on Pre-neoadjuvant Chemotherapy MRI for Response Evaluation of Breast Cancer. Technol Cancer Res Treat 2021; 20:15330338211039129. [PMID: 34519583 PMCID: PMC8445528 DOI: 10.1177/15330338211039129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background: Neoadjuvant chemotherapy (NAC) is known to be a suitable treatment and first-line defense for locally advanced breast cancer. However, the NAC response may include unexpected outcomes, and it is not easy to predict the NAC response precisely. Especially, early detection of those patients who do not benefit from NAC is needed to reduce unnecessary therapy and side effects. Objective: The purpose of this study was to determine whether the pretreatment apparent diffusion coefficient (ADC) value is effective for predicting the response of breast cancer to NAC. Method: Forty-nine breast cancer cases with pre- and post-NAC breast MRI were enrolled. MRI was performed using a 1.5-T scanner with the basic protocol including diffusion-weighted imaging. ADC difference value (ADC-diff) was calculated in all cases. Results: ADC-diff was high in complete response and partial response cases (p < .05). ADC-diff correlated with the DWI rim sign, with a positive DWI rim sign being associated with a higher ADC-diff (p < .05). Conclusion: High-ADC difference value on the pretreatment MRI can provide information for a better response of NAC on breast cancer.
Collapse
Affiliation(s)
- Bo Bae Choi
- 26715Chungnam National University Hospital, Daejeon, Republic of Korea
| |
Collapse
|
23
|
Huang Y, Chen W, Zhang X, He S, Shao N, Shi H, Lin Z, Wu X, Li T, Lin H, Lin Y. Prediction of Tumor Shrinkage Pattern to Neoadjuvant Chemotherapy Using a Multiparametric MRI-Based Machine Learning Model in Patients With Breast Cancer. Front Bioeng Biotechnol 2021; 9:662749. [PMID: 34295877 PMCID: PMC8291046 DOI: 10.3389/fbioe.2021.662749] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 06/07/2021] [Indexed: 01/01/2023] Open
Abstract
Aim: After neoadjuvant chemotherapy (NACT), tumor shrinkage pattern is a more reasonable outcome to decide a possible breast-conserving surgery (BCS) than pathological complete response (pCR). The aim of this article was to establish a machine learning model combining radiomics features from multiparametric MRI (mpMRI) and clinicopathologic characteristics, for early prediction of tumor shrinkage pattern prior to NACT in breast cancer. Materials and Methods: This study included 199 patients with breast cancer who successfully completed NACT and underwent following breast surgery. For each patient, 4,198 radiomics features were extracted from the segmented 3D regions of interest (ROI) in mpMRI sequences such as T1-weighted dynamic contrast-enhanced imaging (T1-DCE), fat-suppressed T2-weighted imaging (T2WI), and apparent diffusion coefficient (ADC) map. The feature selection and supervised machine learning algorithms were used to identify the predictors correlated with tumor shrinkage pattern as follows: (1) reducing the feature dimension by using ANOVA and the least absolute shrinkage and selection operator (LASSO) with 10-fold cross-validation, (2) splitting the dataset into a training dataset and testing dataset, and constructing prediction models using 12 classification algorithms, and (3) assessing the model performance through an area under the curve (AUC), accuracy, sensitivity, and specificity. We also compared the most discriminative model in different molecular subtypes of breast cancer. Results: The Multilayer Perception (MLP) neural network achieved higher AUC and accuracy than other classifiers. The radiomics model achieved a mean AUC of 0.975 (accuracy = 0.912) on the training dataset and 0.900 (accuracy = 0.828) on the testing dataset with 30-round 6-fold cross-validation. When incorporating clinicopathologic characteristics, the mean AUC was 0.985 (accuracy = 0.930) on the training dataset and 0.939 (accuracy = 0.870) on the testing dataset. The model further achieved good AUC on the testing dataset with 30-round 5-fold cross-validation in three molecular subtypes of breast cancer as following: (1) HR+/HER2–: 0.901 (accuracy = 0.816), (2) HER2+: 0.940 (accuracy = 0.865), and (3) TN: 0.837 (accuracy = 0.811). Conclusions: It is feasible that our machine learning model combining radiomics features and clinical characteristics could provide a potential tool to predict tumor shrinkage patterns prior to NACT. Our prediction model will be valuable in guiding NACT and surgical treatment in breast cancer.
Collapse
Affiliation(s)
- Yuhong Huang
- Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Wenben Chen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
| | - Xiaoling Zhang
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Shaofu He
- Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Nan Shao
- Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Huijuan Shi
- Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Zhenzhe Lin
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
| | - Xueting Wu
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
| | - Tongkeng Li
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
| | - Haotian Lin
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.,Center for Precision Medicine, Sun Yat-sen University, Guangzhou, China
| | - Ying Lin
- Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| |
Collapse
|
24
|
Kim JJ, Kim JY. Fusion of high b-value diffusion-weighted and unenhanced T1-weighted images to diagnose invasive breast cancer: factors associated with false-negative results. Eur Radiol 2021; 31:4860-4871. [PMID: 33443601 DOI: 10.1007/s00330-020-07644-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 11/06/2020] [Accepted: 12/17/2020] [Indexed: 10/22/2022]
Abstract
OBJECTIVES We sought factors associated with false-negative results in the diagnosis of invasive breast cancer via non-contrast breast magnetic resonance imaging (MRI) using fused high b-value diffusion-weighted imaging (DWI) and unenhanced T1-weighted images (T1WI). METHODS Between 2018 and 2019, 316 consecutive women (mean age, 54.6 years) with invasive breast cancer who underwent preoperative breast MRI, including fused high b-value DWI and unenhanced T1WI, were retrospectively evaluated. Malignancy confidence ratings of the most suspicious breast lesions evident on fused DWI were derived by two radiologists using a 6-point Likert-type scale. Both clinicopathological and imaging features were analyzed. Multivariate regression analysis was performed to identify factors associated with false-negative DWI results in the diagnosis of invasive breast cancer. RESULTS Of the 316 breast cancers, fused DWI yielded 289 (91.5%) true-positive and 27 (8.5%) false-negative results. Multivariate analysis showed that small tumor size (≤ 1 cm) (odds ratio [OR], 5.95; 95% confidence interval [CI], 2.11, 16.81; p = 0.001), presence of calcifications in the tumor (OR, 3.41; 95% CI, 1.27, 9.15; p = 0.015), and a moderate/marked background diffusion signal (ORs, 4.23 and 19.18; 95% CI, 1.31, 13.67 and 6.51, 56.46; p = 0.016 and p < 0.001, respectively) were significantly associated with false-negative results. In subgroup analysis of 141 screening-detected cancers, a marked background diffusion signal (OR, 7.94; 95% CI, 2.30, 27.35; p = 0.001) remained significantly associated with false-negative results in the multivariate analysis. CONCLUSIONS In addition to histopathological features, a higher background diffusion signal was associated with false-negative results in the diagnosis of invasive breast cancer via non-contrast MRI using fused high b-value DWI and unenhanced T1WI. KEY POINTS • Subcentimeter tumors and presence of calcifications in the tumor are associated with false-negative diffusion-weighted imaging results in the diagnosis of invasive breast cancer. • A higher degree of background diffusion signal may lead to false-negative interpretation of diffusion-weighted imaging in patients with invasive breast cancer.
Collapse
Affiliation(s)
- Jin Joo Kim
- Department of Radiology, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, 1-10, Ami-Dong, Seo-gu, Busan, 602-739, Republic of Korea
| | - Jin You Kim
- Department of Radiology, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, 1-10, Ami-Dong, Seo-gu, Busan, 602-739, Republic of Korea.
| |
Collapse
|
25
|
Barba D, León-Sosa A, Lugo P, Suquillo D, Torres F, Surre F, Trojman L, Caicedo A. Breast cancer, screening and diagnostic tools: All you need to know. Crit Rev Oncol Hematol 2020; 157:103174. [PMID: 33249359 DOI: 10.1016/j.critrevonc.2020.103174] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Revised: 09/18/2020] [Accepted: 11/05/2020] [Indexed: 02/06/2023] Open
Abstract
Breast cancer is one of the most frequent malignancies among women worldwide. Methods for screening and diagnosis allow health care professionals to provide personalized treatments that improve the outcome and survival. Scientists and physicians are working side-by-side to develop evidence-based guidelines and equipment to detect cancer earlier. However, the lack of comprehensive interdisciplinary information and understanding between biomedical, medical, and technology professionals makes innovation of new screening and diagnosis tools difficult. This critical review gathers, for the first time, information concerning normal breast and cancer biology, established and emerging methods for screening and diagnosis, staging and grading, molecular and genetic biomarkers. Our purpose is to address key interdisciplinary information about these methods for physicians and scientists. Only the multidisciplinary interaction and communication between scientists, health care professionals, technical experts and patients will lead to the development of better detection tools and methods for an improved screening and early diagnosis.
Collapse
Affiliation(s)
- Diego Barba
- Escuela de Medicina, Universidad San Francisco de Quito USFQ, Quito, Ecuador; Instituto de Investigaciones en Biomedicina, Universidad San Francisco de Quito USFQ, Quito, Ecuador; Mito-Act Research Consortium, Quito, Ecuador
| | - Ariana León-Sosa
- Escuela de Medicina, Universidad San Francisco de Quito USFQ, Quito, Ecuador; Instituto de Investigaciones en Biomedicina, Universidad San Francisco de Quito USFQ, Quito, Ecuador; Mito-Act Research Consortium, Quito, Ecuador
| | - Paulina Lugo
- Hospital de los Valles HDLV, Quito, Ecuador; Fundación Ayuda Familiar y Comunitaria AFAC, Quito, Ecuador
| | - Daniela Suquillo
- Instituto de Investigaciones en Biomedicina, Universidad San Francisco de Quito USFQ, Quito, Ecuador; Mito-Act Research Consortium, Quito, Ecuador; Ingeniería en Procesos Biotecnológicos, Colegio de Ciencias Biológicas y Ambientales COCIBA, Universidad San Francisco de Quito USFQ, Quito, Ecuador
| | - Fernando Torres
- Escuela de Medicina, Universidad San Francisco de Quito USFQ, Quito, Ecuador; Hospital de los Valles HDLV, Quito, Ecuador
| | - Frederic Surre
- University of Glasgow, James Watt School of Engineering, Glasgow, G12 8QQ, United Kingdom
| | - Lionel Trojman
- LISITE, Isep, 75006, Paris, France; Universidad San Francisco de Quito USFQ, Colegio de Ciencias e Ingenierías Politécnico - USFQ, Instituto de Micro y Nanoelectrónica, IMNE, USFQ, Quito, Ecuador
| | - Andrés Caicedo
- Escuela de Medicina, Universidad San Francisco de Quito USFQ, Quito, Ecuador; Instituto de Investigaciones en Biomedicina, Universidad San Francisco de Quito USFQ, Quito, Ecuador; Mito-Act Research Consortium, Quito, Ecuador; Sistemas Médicos SIME, Universidad San Francisco de Quito USFQ, Quito, Ecuador.
| |
Collapse
|
26
|
Lee SH, Shin HJ, Moon WK. Diffusion-Weighted Magnetic Resonance Imaging of the Breast: Standardization of Image Acquisition and Interpretation. Korean J Radiol 2020; 22:9-22. [PMID: 32901461 PMCID: PMC7772373 DOI: 10.3348/kjr.2020.0093] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Revised: 05/06/2020] [Accepted: 05/09/2020] [Indexed: 12/12/2022] Open
Abstract
Diffusion-weighted (DW) magnetic resonance imaging (MRI) is a rapid, unenhanced imaging technique that measures the motion of water molecules within tissues and provides information regarding the cell density and tissue microstructure. DW MRI has demonstrated the potential to improve the specificity of breast MRI, facilitate the evaluation of tumor response to neoadjuvant chemotherapy and can be employed in unenhanced MRI screening. However, standardization of the acquisition and interpretation of DW MRI is challenging. Recently, the European Society of Breast Radiology issued a consensus statement, which described the acquisition parameters and interpretation of DW MRI. The current article describes the basic principles, standardized acquisition protocols and interpretation guidelines, and the clinical applications of DW MRI in breast imaging.
Collapse
Affiliation(s)
- Su Hyun Lee
- Department of Radiology, Seoul National University Hospital, Seoul, Korea
| | - Hee Jung Shin
- Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Woo Kyung Moon
- Department of Radiology, Seoul National University Hospital, Seoul, Korea.
| |
Collapse
|
27
|
Surov A, Wienke A, Meyer HJ. Pretreatment apparent diffusion coefficient does not predict therapy response to neoadjuvant chemotherapy in breast cancer. Breast 2020; 53:59-67. [PMID: 32652460 PMCID: PMC7375564 DOI: 10.1016/j.breast.2020.06.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 05/30/2020] [Accepted: 06/01/2020] [Indexed: 12/12/2022] Open
Abstract
Background Some reports indicated that apparent diffusion coefficient can predict pathologic response to treatment in breast cancer (BC). The purpose of the present meta-analysis was to provide evident data regarding use of ADC values for prediction of treatment response in BC. Methods MEDLINE library, EMBASE and SCOPUS databases were screened for associations between ADC and treatment response for neoadjuvant chemotherapy in breast cancer (BC) up to March 2020. Overall, 22 studies met the inclusion criteria. For the present analysis, the following data were extracted from the collected studies: authors, year of publication, study design, number of patients/lesions, mean and standard deviation of the pretreatment ADC values. The methodological quality of the included studies was checked according to the QUADAS-2 instrument. The meta-analysis was undertaken by using RevMan 5.3 software. DerSimonian and Laird random-effects models with inverse-variance weights were used without any further correction to account for the heterogeneity between the studies. Mean ADC values including 95% confidence intervals were calculated separately for responders and non responders. Results The acquired 22 studies comprised 1827 patients with different BC. Of the 1827 patients, 650 (35.6%) were reported as responders and 1177 (64.4%) as non-responders to the neoadjuvant chemotherapy. The pooled calculated pretreatment mean ADC value of BC in responders was 0.98 (95% CI = [0.94; 1.03]). In non-responders, it was 1.05 (95% CI = [1.00; 1.10]). The ADC values of the groups overlapped significantly. Conclusion Pretreatment ADC alone cannot predict response to neoadjuvant chemotherapy in BC.
Collapse
Affiliation(s)
- Alexey Surov
- Department of Radiology and Nuclear Medicine, Otto-von-Guericke University of Magdeburg, Germany.
| | - Andreas Wienke
- Department of Diagnostic and Interventional Radiology, University of Leipzig, Germany.
| | - Hans Jonas Meyer
- Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther-University Halle-Wittenberg, Germany.
| |
Collapse
|
28
|
Nadrljanski MM, Milosevic ZC. Tumor texture parameters of invasive ductal breast carcinoma in neoadjuvant chemotherapy: early identification of non-responders on breast MRI. Clin Imaging 2020; 65:119-123. [PMID: 32446129 DOI: 10.1016/j.clinimag.2020.04.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 03/22/2020] [Accepted: 04/07/2020] [Indexed: 02/03/2023]
Abstract
PURPOSE Texture analysis (TA) parameters (variance of SI, mean of gradient, variance of gradient, kurtosis of SI, and entropy) in patients with invasive ductal carcinoma (IDC) contribute to objective assessment of neoadjuvant chemotherapy (NACT) activity. The objective was to assess TA parameters in early identification of non-responders (NR) in NACT, after the 2nd cycle of NACT. MATERIAL AND METHODS Fifty patients (N = 50) were included in the retrospective analysis of baseline and MRI following the 2nd cycle of NACT. TA parameters were computed and correlated to the lesion size and DWI-ADC in NR (N1 = 25). Additional matched responders (R, N2 = 25) assessed for the same parameters, served as the control group. RESULTS Tumor size and ADC did not change significantly in NR after the 2nd cycle of NACT (2.88 ± 0.38 vs. 2.76 ± 0.36 [cm], p = 0.131; 1.01 ± 0.14 vs. 1.05 ± 0.13 [mm2/s × 10-3], p = 0.363), but TA parameters changed significantly: variance of gradient (346.5 ± 12.6 vs. 355.6 ± 16.9, p = 0.01), kurtosis of SI (1.47 ± 0.09 vs. 1.54 ± 0.11, p = 0.02), entropy LH (60.39 ± 4.34 vs. 64.42 ± 3.05, p = 0.001) and entropy HL (61.02 ± 5.51 vs. 65.63 ± 3.63, p < 0.00001). TA parameters, particularly entropy (EN LH 64.42 ± 3.05 vs. 61.59 ± 1.76, p < 0.0001; EN HL 65.63 ± 3.63 vs. 62.89 ± 2.05, p < 0.0001), significantly differ between NR and R in early response assessment. CONCLUSION Entropy, kurtosis of SI and variance of gradient tend to increase in NR. TA parameters significantly differ between NR and R after the 2nd cycle of NACT. TA parameters, related to morpho-functional parameters may contribute to early NR identification.
Collapse
Affiliation(s)
- Mirjan M Nadrljanski
- Institute of Oncology and Radiology of Serbia, Clinic for Radiology and Radiation Oncology, Dept. of Radiology, Dept. of Breast Imaging, School of Medicine, University of Belgrade, Belgrade, Serbia.
| | - Zorica C Milosevic
- Institute of Oncology and Radiology of Serbia, Clinic for Radiology and Radiation Oncology, Dept. of Radiology, Dept. of Breast Imaging, School of Medicine, University of Belgrade, Belgrade, Serbia
| |
Collapse
|
29
|
Reig B, Heacock L, Lewin A, Cho N, Moy L. Role of MRI to Assess Response to Neoadjuvant Therapy for Breast Cancer. J Magn Reson Imaging 2020; 52. [DOI: 10.1002/jmri.27145] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Revised: 03/01/2020] [Accepted: 03/02/2020] [Indexed: 12/25/2022] Open
Affiliation(s)
- Beatriu Reig
- Department of Radiology New York University Grossman School of Medicine New York New York USA
- New York University Laura and Isaac Perlmutter Cancer Center New York New York USA
| | - Laura Heacock
- Department of Radiology New York University Grossman School of Medicine New York New York USA
- New York University Laura and Isaac Perlmutter Cancer Center New York New York USA
| | - Alana Lewin
- Department of Radiology New York University Grossman School of Medicine New York New York USA
- New York University Laura and Isaac Perlmutter Cancer Center New York New York USA
| | - Nariya Cho
- Department of Radiology Seoul National University Hospital Seoul Republic of Korea
- Department of Radiology Seoul National University College of Medicine Seoul Republic of Korea
| | - Linda Moy
- Department of Radiology New York University Grossman School of Medicine New York New York USA
- New York University Laura and Isaac Perlmutter Cancer Center New York New York USA
- Bernard and Irene Schwartz Center for Biomedical Imaging Department of Radiology, New York University Grossman School of Medicine New York New York USA
- Center for Advanced Imaging Innovation and Research (CAI2 R) New York University Grossman School of Medicine New York New York USA
| |
Collapse
|
30
|
Mori N, Mugikura S, Miyashita M, Mori Y, Maekawa Y, Nagasaka T, Takase K. Turbo Spin-echo Diffusion-weighted Imaging Compared with Single-shot Echo-planar Diffusion-weighted Imaging: Image Quality and Diagnostic Performance When Differentiating between Ductal Carcinoma in situ and Invasive Ductal Carcinoma. Magn Reson Med Sci 2020; 20:60-68. [PMID: 32147641 PMCID: PMC7952202 DOI: 10.2463/mrms.mp.2019-0195] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Purpose: To compare the image quality between turbo spin-echo (TSE)-diffusion weighted imaging (DWI) and single-shot echo-planar imaging (EPI)-DWI, and to verify the diagnostic performance of the apparent diffusion coefficient (ADC) parameters of the two techniques by using histogram analysis in terms of differentiation between ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) lesions. Methods: Ninety-four women with 94 lesions diagnosed as breast cancer by surgery underwent IRB-approved preoperative magnetic resonance imaging, including TSE and EPI-DWI with b-values of 50 and 850 s/mm2. Twenty lesions were identified as DCIS and 74 as IDC. Image quality [signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and geometric distortion] was evaluated quantitatively and compared between the TSE and EPI-DWI. A histogram analysis of the entire tumor voxel-based ADC data was performed, and the 10th, 25th, 50th, 75th, and 90th percentile values of each technique were compared between DCIS and IDC lesions. Results: The SNR and CNR of TSE-DWI were significantly higher than those of EPI-DWI (P < 0.0001 and < 0.0001). The geometric distortion of TSE-DWI was significantly lower than that of EPI-DWI (P < 0.0001). In TSE-DWI, the 10th, 25th, 50th, and 75th percentile values were significantly different between the DCIS and IDC lesions (P = 0.0010, 0.0004, 0.0008, and 0.0044, respectively). In EPI-DWI, the 50th and 75th percentile values were significantly different between the two groups (P = 0.0009 and 0.0093). There was no significant difference in the area under the curve of the receiver operating characteristic analysis of the 10th, 25th, 50th, and 75th percentile values of TSE-DWI, and the 50th and 75th percentile values of EPI-DWI (P = 0.29). Conclusion: The image quality of TSE-DWI was better than that of EPI-DWI. DCIS lesions were distinguished from IDC lesions with a wider range of percentile values in TSE-DWI than in EPI-DWI, although diagnostic performance was not significantly different between the techniques.
Collapse
Affiliation(s)
- Naoko Mori
- Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine
| | - Shunji Mugikura
- Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine
| | - Minoru Miyashita
- Department of Surgical Oncology, Tohoku University Graduate School of Medicine
| | - Yu Mori
- Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine
| | - Yui Maekawa
- Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine
| | - Tatsuo Nagasaka
- Department of Radiological Technology, Tohoku University Graduate School of Medicine
| | - Kei Takase
- Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine
| |
Collapse
|
31
|
Baltzer P, Mann RM, Iima M, Sigmund EE, Clauser P, Gilbert FJ, Martincich L, Partridge SC, Patterson A, Pinker K, Thibault F, Camps-Herrero J, Le Bihan D. Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group. Eur Radiol 2019; 30:1436-1450. [PMID: 31786616 PMCID: PMC7033067 DOI: 10.1007/s00330-019-06510-3] [Citation(s) in RCA: 221] [Impact Index Per Article: 44.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Revised: 09/03/2019] [Accepted: 10/10/2019] [Indexed: 01/03/2023]
Abstract
The European Society of Breast Radiology (EUSOBI) established an International Breast DWI working group. The working group consists of clinical breast MRI experts, MRI physicists, and representatives from large vendors of MRI equipment, invited based upon proven expertise in breast MRI and/or in particular breast DWI, representing 25 sites from 16 countries. The aims of the working group are (a) to promote the use of breast DWI into clinical practice by issuing consensus statements and initiate collaborative research where appropriate; (b) to define necessary standards and provide practical guidance for clinical application of breast DWI; (c) to develop a standardized and translatable multisite multivendor quality assurance protocol, especially for multisite research studies; (d) to find consensus on optimal methods for image processing/analysis, visualization, and interpretation; and (e) to work collaboratively with system vendors to improve breast DWI sequences. First consensus recommendations, presented in this paper, include acquisition parameters for standard breast DWI sequences including specifications of b values, fat saturation, spatial resolution, and repetition and echo times. To describe lesions in an objective way, levels of diffusion restriction/hindrance in the breast have been defined based on the published literature on breast DWI. The use of a small ROI placed on the darkest part of the lesion on the ADC map, avoiding necrotic, noisy or non-enhancing lesion voxels is currently recommended. The working group emphasizes the need for standardization and quality assurance before ADC thresholds are applied. The working group encourages further research in advanced diffusion techniques and tailored DWI strategies for specific indications. Key Points • The working group considers breast DWI an essential part of a multiparametric breast MRI protocol and encourages its use. • Basic requirements for routine clinical application of breast DWI are provided, including recommendations on b values, fat saturation, spatial resolution, and other sequence parameters. • Diffusion levels in breast lesions are defined based on meta-analysis data and methods to obtain a reliable ADC value are detailed.
Collapse
Affiliation(s)
- Pascal Baltzer
- Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna/Vienna General Hospital, Wien, Austria
| | - Ritse M Mann
- Department of Radiology, Radboud University Medical Centre, Nijmegen, Netherlands. .,Department of Radiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
| | - Mami Iima
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Eric E Sigmund
- Department of Radiology, New York University School of Medicine, NYU Langone Health, Ney York, NY, 10016, USA
| | - Paola Clauser
- Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna/Vienna General Hospital, Wien, Austria
| | - Fiona J Gilbert
- Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | | | - Savannah C Partridge
- Department of Radiology, University of Washington School of Medicine, Seattle, Washington, USA
| | - Andrew Patterson
- Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | - Katja Pinker
- Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna/Vienna General Hospital, Wien, Austria.,MSKCC, New York, NY, 10065, USA
| | | | | | - Denis Le Bihan
- NeuroSpin, Frédéric Joliot Institute, Gif Sur Yvette, France
| | | |
Collapse
|
32
|
Pereira NP, Curi C, Osório CABT, Marques EF, Makdissi FB, Pinker K, Bitencourt AGV. Diffusion-Weighted Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction of Pathological Response - A Prospective Study. Sci Rep 2019; 9:16372. [PMID: 31705004 PMCID: PMC6841711 DOI: 10.1038/s41598-019-52785-3] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 10/23/2019] [Indexed: 12/22/2022] Open
Abstract
The purpose of this study was to evaluate the capacity of diffusion-weighted magnetic resonance imaging (DW-MRI) for early prediction of pathological response in breast cancer patients undergoing neoadjuvant chemotherapy (NCT). This prospective unicentric study evaluated 62 patients who underwent NCT. MRI was performed prior to the start of treatment (MR1), after the first NCT cycle (MR2), and upon completion of NCT (MR3). Pathological response was used as the gold-standard. Patients’ median age was 45.5 years and the median tumor size was 40 mm. Twenty-four (38.7%) tumors presented complete pathological response (pCR). The percent increase in apparent diffusion coefficient (ADC) value between MR1 and MR2 was higher in the pCR group (p < 0.001). When the minimum increase in ADC between MR1 and MR2 was set at 25%, sensitivity was 83%, specificity was 84%, positive predictive value was 77%, negative predictive value was 89%, and accuracy was 84% for an early prediction of pCR to NCT. Meanwhile, there were no significant changes in major tumor dimensions between MR1 and MR2. In conclusion, an increase in ADC after the first cycle of NCT correlates well with pCR after the chemotherapy in our cohort, precedes reduction in tumor size on conventional MRI, and may therefore be used as an early predictor of treatment response.
Collapse
Affiliation(s)
- Nara P Pereira
- Department of Imaging - A.C.Camargo Cancer Center, R. Prof. Antônio Prudente, 211. Zip Code: 01509-010, São Paulo, SP, Brazil
| | - Carla Curi
- Breast Cancer Reference Center - A.C.Camargo Cancer Center, R. Prof. Antônio Prudente, 211. Zip Code: 01509-010, São Paulo, SP, Brazil
| | - Cynthia A B T Osório
- Department of Pathology - A.C.Camargo Cancer Center, R. Prof. Antônio Prudente, 211. Zip Code: 01509-010, São Paulo, SP, Brazil
| | - Elvira F Marques
- Department of Imaging - A.C.Camargo Cancer Center, R. Prof. Antônio Prudente, 211. Zip Code: 01509-010, São Paulo, SP, Brazil
| | - Fabiana B Makdissi
- Breast Cancer Reference Center - A.C.Camargo Cancer Center, R. Prof. Antônio Prudente, 211. Zip Code: 01509-010, São Paulo, SP, Brazil
| | - Katja Pinker
- Department of Radiology, Breast Imaging Service - Memorial Sloan-Kettering Cancer Center 300 E 66th St. Zip Code, 10065, New York, NY, USA
| | - Almir G V Bitencourt
- Department of Imaging - A.C.Camargo Cancer Center, R. Prof. Antônio Prudente, 211. Zip Code: 01509-010, São Paulo, SP, Brazil. .,Department of Radiology, Breast Imaging Service - Memorial Sloan-Kettering Cancer Center 300 E 66th St. Zip Code, 10065, New York, NY, USA.
| |
Collapse
|
33
|
Iima M, Honda M, Sigmund EE, Ohno Kishimoto A, Kataoka M, Togashi K. Diffusion MRI of the breast: Current status and future directions. J Magn Reson Imaging 2019; 52:70-90. [PMID: 31520518 DOI: 10.1002/jmri.26908] [Citation(s) in RCA: 88] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Accepted: 08/12/2019] [Indexed: 12/30/2022] Open
Abstract
Diffusion-weighted imaging (DWI) is increasingly being incorporated into routine breast MRI protocols in many institutions worldwide, and there are abundant breast DWI indications ranging from lesion detection and distinguishing malignant from benign tumors to assessing prognostic biomarkers of breast cancer and predicting treatment response. DWI has the potential to serve as a noncontrast MR screening method. Beyond apparent diffusion coefficient (ADC) mapping, which is a commonly used quantitative DWI measure, advanced DWI models such as intravoxel incoherent motion (IVIM), non-Gaussian diffusion MRI, and diffusion tensor imaging (DTI) are extensively exploited in this field, allowing the characterization of tissue perfusion and architecture and improving diagnostic accuracy without the use of contrast agents. This review will give a summary of the clinical literature along with future directions. Level of Evidence: 5 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2020;52:70-90.
Collapse
Affiliation(s)
- Mami Iima
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.,Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Maya Honda
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Eric E Sigmund
- Department of Radiology, NYU Langone Health, New York, New York, USA.,Center for Advanced Imaging and Innovation (CAI2R), New York, New York, USA
| | - Ayami Ohno Kishimoto
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Masako Kataoka
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Kaori Togashi
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
34
|
Tsukada H, Tsukada J, Schrading S, Strobel K, Okamoto T, Kuhl CK. Accuracy of multi-parametric breast MR imaging for predicting pathological complete response of operable breast cancer prior to neoadjuvant systemic therapy. Magn Reson Imaging 2019; 62:242-248. [PMID: 31352016 DOI: 10.1016/j.mri.2019.07.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 07/12/2019] [Accepted: 07/13/2019] [Indexed: 10/26/2022]
Abstract
OBJECTIVES To evaluate whether multiparametric breast-MRI, obtained before the initiation of neoadjuvant systemic therapy (NST) for operable breast cancer, predicts which cancer will achieve a pathological complete response (pCR) after the completion of NST. METHODS This was an IRB-approved retrospective study on 31 consecutive patients (median age, 56 years) with operable invasive breast cancer (median size: 22 mm; triple-negative: 11/31 [35%], HER2-positive: 7/31 [23%], triple-positive: 13/31 [42%]) who underwent multiparametric DCE-MRI before the initiation of NST. The MRI protocol consisted of high-resolution dynamic contrast-enhanced MRI (DCE-MRI), T2-TSE, and DWI (b-values 0, 100, 800 s/mm2). The results of surgical pathology after the completion of NST served as a standard of reference. Patient characteristics (age and menopausal status), pathological tumor characteristics (type, stage, nuclear grade, ER/PR and HER2 receptor status, and Ki-67 staining), and MRI characteristics (size, morphology, T2 signal intensity, enhancement kinetics, and ADC values) before NST were evaluated and compared between patients achieving pCR vs. non-pCR. RESULTS Among 31 patients, 17 achieved pCR (55%) and 14 non-pCR (45%). No correlation was observed between patient- or tumor pathology-derived characteristics and pCR vs. non-pCR. Among MRI-derived tumor characteristics, tumor growth orientation parallel to Cooper's ligaments (p = 0.002) and wash-out rates (p = 0.019) correlated with pCR. Pre-NST ADC values were lower in patients achieving pCR (P = 0.086). CONCLUSIONS A tumor growth pattern parallel with Cooper's ligaments and a fast wash-out rate on pre-treatment multiparametric MRI are predictive of pCR and more closely associated with pCR than ADC values.
Collapse
Affiliation(s)
- Hiroko Tsukada
- Department of Diagnostic and Interventional Radiology, Hospital of the University of Aachen, RWTH, Pauwelsstrasse 30, 52074 Aachen, Germany; Department of Surgery II, School of Medicine, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, 162-8666 Tokyo, Japan.
| | - Jitsuro Tsukada
- Department of Radiology, Nihon University School of Medicine, 30-1, Oyaguchi Kami-Cho, Itabashi-ku, 173-8610 Tokyo, Japan
| | - Simone Schrading
- Department of Diagnostic and Interventional Radiology, Hospital of the University of Aachen, RWTH, Pauwelsstrasse 30, 52074 Aachen, Germany
| | - Kevin Strobel
- Department of Diagnostic and Interventional Radiology, Hospital of the University of Aachen, RWTH, Pauwelsstrasse 30, 52074 Aachen, Germany
| | - Takahiro Okamoto
- Department of Surgery II, School of Medicine, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, 162-8666 Tokyo, Japan
| | - Christiane K Kuhl
- Department of Diagnostic and Interventional Radiology, Hospital of the University of Aachen, RWTH, Pauwelsstrasse 30, 52074 Aachen, Germany
| |
Collapse
|
35
|
Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology 2018; 289:618-627. [PMID: 30179110 PMCID: PMC6283325 DOI: 10.1148/radiol.2018180273] [Citation(s) in RCA: 156] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Revised: 07/12/2018] [Accepted: 07/18/2018] [Indexed: 01/06/2023]
Abstract
Purpose To determine if the change in tumor apparent diffusion coefficient (ADC) at diffusion-weighted (DW) MRI is predictive of pathologic complete response (pCR) to neoadjuvant chemotherapy for breast cancer. Materials and Methods In this prospective multicenter study, 272 consecutive women with breast cancer were enrolled at 10 institutions (from August 2012 to January 2015) and were randomized to treatment with 12 weekly doses of paclitaxel (with or without an experimental agent), followed by 12 weeks of treatment with four cycles of anthracycline. Each woman underwent breast DW MRI before treatment, at early treatment (3 weeks), at midtreatment (12 weeks), and after treatment. Percentage change in tumor ADC from that before treatment (ΔADC) was measured at each time point. Performance for predicting pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and according to tumor hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) disease subtype. Results The final analysis included 242 patients with evaluable serial imaging data, with a mean age of 48 years ± 10 (standard deviation); 99 patients had HR-positive (hereafter, HR+)/HER2-negative (hereafter, HER2-) disease, 77 patients had HR-/HER2- disease, 42 patients had HR+/HER2+ disease, and 24 patients had HR-/HER2+ disease. Eighty (33%) of 242 patients experienced pCR. Overall, ΔADC was moderately predictive of pCR at midtreatment/12 weeks (AUC = 0.60; 95% confidence interval [CI]: 0.52, 0.68; P = .017) and after treatment (AUC = 0.61; 95% CI: 0.52, 0.69; P = .013). Across the four disease subtypes, midtreatment ΔADC was predictive only for HR+/HER2- tumors (AUC = 0.76; 95% CI: 0.62, 0.89; P < .001). In a test subset, a model combining tumor subtype and midtreatment ΔADC improved predictive performance (AUC = 0.72; 95% CI: 0.61, 0.83) over ΔADC alone (AUC = 0.57; 95% CI: 0.44, 0.70; P = .032.). Conclusion After 12 weeks of therapy, change in breast tumor apparent diffusion coefficient at MRI predicts complete pathologic response to neoadjuvant chemotherapy. © RSNA, 2018 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Savannah C. Partridge
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Zheng Zhang
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - David C. Newitt
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Jessica E. Gibbs
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Thomas L. Chenevert
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Mark A. Rosen
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Patrick J. Bolan
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Helga S. Marques
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Justin Romanoff
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Lisa Cimino
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Bonnie N. Joe
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Heidi R. Umphrey
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Haydee Ojeda-Fournier
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Basak Dogan
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Karen Oh
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Hiroyuki Abe
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Jennifer S. Drukteinis
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Laura J. Esserman
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - Nola M. Hylton
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| | - For the ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators
- From the Department of Radiology, University of Washington, 825
Eastlake Ave E, G2-600, Seattle, WA 98109 (S.C.P.); Department of Biostatistics
(Z.Z.) and Center for Statistical Sciences (Z.Z., H.S.M., J.R.), Brown
University, Providence, RI; American College of Radiology Imaging Network
(ACRIN), Reston, Va (Z.Z., H.S.M., J.R.); Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San Francisco, Calif (D.C.N.,
J.E.G., B.N.J., L.J.E., N.M.H.); Department of Radiology/MRI, University of
Michigan, Ann Arbor, Mich (T.L.C.); Department of Radiology, University of
Pennsylvania, Philadelphia, Pa (M.A.R.); Department of Radiology, Center for
Magnetic Resonance Research, University of Minnesota, Minneapolis, Minn
(P.J.B.); American College of Radiology and ECOG-ACRIN Cancer Research Group,
Reston, Va (L.C.); Department of Radiology, University of Alabama, Birmingham,
Birmingham, Ala (H.R.U.); Department of Radiology, University of California, San
Diego, San Diego, Calif (H.O.); Department of Radiology, University of Texas MD
Anderson Cancer Center, Houston, Tex and the University of Texas Southwestern
Medical Center, Dallas, Tex (B.D.); Department of Radiology, Oregon Health and
Science University, Portland, Ore (K.O.); Department of Radiology, University of
Chicago, Chicago, Ill (H.A.); and Department of Diagnostic Radiology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, Fla and Department of
Women’s Imaging, St Joseph’s Women’s Hospital, Tampa, Fla (J.S.D.)
| |
Collapse
|
36
|
Yuan L, Li JJ, Li CQ, Yan CG, Cheng ZL, Wu YK, Hao P, Lin BQ, Xu YK. Diffusion-weighted MR imaging of locally advanced breast carcinoma: the optimal time window of predicting the early response to neoadjuvant chemotherapy. Cancer Imaging 2018; 18:38. [PMID: 30373679 PMCID: PMC6206724 DOI: 10.1186/s40644-018-0173-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Accepted: 10/16/2018] [Indexed: 02/05/2023] Open
Abstract
Background It is very difficult to predict the early response to NAC only on the basis of change in tumor size. ADC value derived from DWI promises to be a valuable parameter for evaluating the early response to treatment. This study aims to establish the optimal time window of predicting the early response to neoadjuvant chemotherapy (NAC) for different subtypes of locally advanced breast carcinoma using diffusion-weighted imaging (DWI). Methods We conducted an institutional review board-approved prospective clinical study of 142 patients with locally advanced breast carcinoma. All patients underwent conventional MR and DW examinations prior to treatment and after first, second, third, fourth, sixth and eighth cycle of NAC. The response to NAC was classified into a pathologic complete response (pCR) and a non-pCR group. DWI parameters were compared between two groups, and the optimal time window for predicting tumor response was established for each chemotherapy regimen. Results For all the genomic subtypes, there were significant differences in baseline ADC value between pCR and non-pCR group (p < 0.05). The time point prior to treatment could be considered as the ideal time point regardless of genomic subtype. In the group that started with taxanes or anthracyclines, for Luminal A or Luminal B subtype, postT1 could be used as the ideal time point during chemotherapy; for Basal-like or HER2-enriched subtype, postT2 as the ideal time point during chemotherapy. In the group that started with taxanes and anthracyclines, for HER2-enriched, Luminal B or Basal-like subtype, postT1 could be used as the ideal time point during chemotherapy; for Luminal A subtype, postT2 as the ideal time point during chemotherapy. Conclusions The time point prior to treatment can be considered as the optimal time point regardless of genomic subtype. For each chemotherapy regimen, the optimal time point during chemotherapy varies across different genomic subtypes.
Collapse
Affiliation(s)
- Li Yuan
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, #1838 Guangzhou Avenue North, Guangzhou City, 510515, Guangdong Province, China.,Department of Radiology, Hainan General Hospital, Haikou, 570311, Hainan Province, China
| | - Jian-Jun Li
- Department of Radiology, Hainan General Hospital, Haikou, 570311, Hainan Province, China
| | - Chang-Qing Li
- Department of Radiology, Hainan General Hospital, Haikou, 570311, Hainan Province, China
| | - Cheng-Gong Yan
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, #1838 Guangzhou Avenue North, Guangzhou City, 510515, Guangdong Province, China
| | - Ze-Long Cheng
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, #1838 Guangzhou Avenue North, Guangzhou City, 510515, Guangdong Province, China
| | - Yuan-Kui Wu
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, #1838 Guangzhou Avenue North, Guangzhou City, 510515, Guangdong Province, China
| | - Peng Hao
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, #1838 Guangzhou Avenue North, Guangzhou City, 510515, Guangdong Province, China
| | - Bing-Quan Lin
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, #1838 Guangzhou Avenue North, Guangzhou City, 510515, Guangdong Province, China
| | - Yi-Kai Xu
- Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, #1838 Guangzhou Avenue North, Guangzhou City, 510515, Guangdong Province, China.
| |
Collapse
|
37
|
Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. J Magn Reson Imaging 2018; 49:1617-1628. [PMID: 30350329 DOI: 10.1002/jmri.26539] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 09/20/2018] [Accepted: 09/22/2018] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Quantitative diffusion-weighted imaging (DWI) MRI is a promising technique for cancer characterization and treatment monitoring. Knowledge of the reproducibility of DWI metrics in breast tumors is necessary to apply DWI as a clinical biomarker. PURPOSE To evaluate the repeatability and reproducibility of breast tumor apparent diffusion coefficient (ADC) in a multi-institution clinical trial setting, using standardized DWI protocols and quality assurance (QA) procedures. STUDY TYPE Prospective. SUBJECTS In all, 89 women from nine institutions undergoing neoadjuvant chemotherapy for invasive breast cancer. FIELD STRENGTH/SEQUENCE DWI was acquired before and after patient repositioning using a four b-value, single-shot echo-planar sequence at 1.5T or 3.0T. ASSESSMENT A QA procedure by trained operators assessed artifacts, fat suppression, and signal-to-noise ratio, and determine study analyzability. Mean tumor ADC was measured via manual segmentation of the multislice tumor region referencing DWI and contrast-enhanced images. Twenty cases were evaluated multiple times to assess intra- and interoperator variability. Segmentation similarity was assessed via the Sørenson-Dice similarity coefficient. STATISTICAL TESTS Repeatability and reproducibility were evaluated using within-subject coefficient of variation (wCV), intraclass correlation coefficient (ICC), agreement index (AI), and repeatability coefficient (RC). Correlations were measured by Pearson's correlation coefficients. RESULTS In all, 71 cases (80%) passed QA evaluation: 44 at 1.5T, 27 at 3.0T; 60 pretreatment, 11 after 3 weeks of taxane-based treatment. ADC repeatability was excellent: wCV = 4.8% (95% confidence interval [CI] 4.0, 5.7%), ICC = 0.97 (95% CI 0.95, 0.98), AI = 0.83 (95% CI 0.76, 0.87), and RC = 0.16 * 10-3 mm2 /sec (95% CI 0.13, 0.19). The results were similar across field strengths and timepoint subgroups. Reproducibility was excellent: interreader ICC = 0.92 (95% CI 0.80, 0.97) and intrareader ICC = 0.91 (95% CI 0.78, 0.96). DATA CONCLUSION Breast tumor ADC can be measured with excellent repeatability and reproducibility in a multi-institution setting using a standardized protocol and QA procedure. Improvements to DWI image quality could reduce loss of data in clinical trials. LEVEL OF EVIDENCE 2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;49:1617-1628.
Collapse
Affiliation(s)
- David C Newitt
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
| | - Zheng Zhang
- Department of Biostatistics, Brown University, Providence, Rhode Island, USA.,Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.,American College of Radiology Imaging Network (ACRIN), Philadelphia, Pennsylvania, USA
| | - Jessica E Gibbs
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
| | | | - Thomas L Chenevert
- Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA
| | - Mark A Rosen
- Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Patrick J Bolan
- Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minnesota, USA
| | - Helga S Marques
- Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.,American College of Radiology Imaging Network (ACRIN), Philadelphia, Pennsylvania, USA
| | - Sheye Aliu
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
| | - Wen Li
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
| | - Lisa Cimino
- American College of Radiology & ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, USA
| | - Bonnie N Joe
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
| | - Heidi Umphrey
- Department of Radiology, University of Alabama, Birmingham, Alabama, USA
| | | | - Basak Dogan
- Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Department of Diagnostic Radiology, University of Texas Southwestern Medical Center, Houston, Texas, USA
| | - Karen Oh
- Department of Radiology, Oregon Health & Science University, Portland, Oregon, USA
| | - Hiroyuki Abe
- Department of Radiology, University of Chicago, Chicago, Illinois, USA
| | - Jennifer Drukteinis
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.,Department of Women's Imaging, St. Joseph's Women's Hospital, Tampa, Florida, USA
| | - Laura J Esserman
- Department of Surgery, University of California, San Francisco, California, USA
| | - Nola M Hylton
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA
| | | |
Collapse
|
38
|
Kousi E, O'Flynn EAM, Borri M, Morgan VA, deSouza NM, Schmidt MA. Pre-treatment functional MRI of breast cancer: T2* evaluation at 3 T and relationship to dynamic contrast-enhanced and diffusion-weighted imaging. Magn Reson Imaging 2018; 52:53-61. [PMID: 29859948 DOI: 10.1016/j.mri.2018.05.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Revised: 05/30/2018] [Accepted: 05/30/2018] [Indexed: 12/11/2022]
Abstract
PURPOSE Baseline T2* relaxation time has been proposed as an imaging biomarker in cancer, in addition to Dynamic Contrast-Enhanced (DCE) MRI and diffusion-weighted imaging (DWI) parameters. The purpose of the current work is to investigate sources of error in T2* measurements and the relationship between T2* and DCE and DWI functional parameters in breast cancer. METHODS Five female volunteers and thirty-two women with biopsy proven breast cancer were scanned at 3 T, with Research Ethics Committee approval. T2* values of the normal breast were acquired from high-resolution, low-resolution and fat-suppressed gradient-echo sequences in volunteers, and compared. In breast cancer patients, pre-treatment T2*, DCE MRI and DWI were performed at baseline. Pathologically complete responders at surgery and non-responders were identified and compared. Principal component analysis (PCA) and cluster analysis (CA) were performed. RESULTS There were no significant differences between T2* values from high-resolution, low-resolution and fat-suppressed datasets (p > 0.05). There were not significant differences between baseline functional parameters in responders and non-responders (p > 0.05). However, there were differences in the relationship between T2* and contrast-agent uptake in responders and non-responders. Voxels of similar characteristics were grouped in 5 clusters, and large intra-tumoural variations of all parameters were demonstrated. CONCLUSION Breast T2* measurements at 3 T are robust, but spatial resolution should be carefully considered. T2* of breast tumours at baseline is unrelated to DCE and DWI parameters and contribute towards describing functional heterogeneity of breast tumours.
Collapse
Affiliation(s)
- Evanthia Kousi
- CR-UK and EPSRC Cancer Imaging Centre, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey SM2 5PT, United Kingdom.
| | - Elizabeth A M O'Flynn
- CR-UK and EPSRC Cancer Imaging Centre, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey SM2 5PT, United Kingdom
| | - Marco Borri
- CR-UK and EPSRC Cancer Imaging Centre, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey SM2 5PT, United Kingdom
| | - Veronica A Morgan
- CR-UK and EPSRC Cancer Imaging Centre, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey SM2 5PT, United Kingdom
| | - Nandita M deSouza
- CR-UK and EPSRC Cancer Imaging Centre, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey SM2 5PT, United Kingdom
| | - Maria A Schmidt
- CR-UK and EPSRC Cancer Imaging Centre, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey SM2 5PT, United Kingdom
| |
Collapse
|
39
|
Nagasaka K, Satake H, Ishigaki S, Kawai H, Naganawa S. Histogram analysis of quantitative pharmacokinetic parameters on DCE-MRI: correlations with prognostic factors and molecular subtypes in breast cancer. Breast Cancer 2018; 26:113-124. [PMID: 30069785 DOI: 10.1007/s12282-018-0899-8] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 07/26/2018] [Indexed: 12/14/2022]
Abstract
BACKGROUND Breast cancer heterogeneity influences poor prognoses thorough therapy resistance. This study quantitatively evaluated intratumoral heterogeneity through a histogram analysis of dynamic contrast-enhanced MRI (DCE-MRI) pharmacokinetic parameters, and determined correlations with prognostic factors and molecular subtypes. METHODS We retrospectively investigated 101 invasive ductal breast cancers from 99 women who underwent preoperative DCE-MRI between July 2012 and November 2014. Pharmacokinetic parameters (Ktrans, kep, and ve) were obtained by the Tofts model. For each parameter, the mean, standard deviation, coefficient of variation, skewness, and kurtosis values of tumor were calculated, and prognostic factors and subtypes associations were assessed. RESULTS The mean of ve was lower in cancers with high Ki-67 than in cancers with low Ki-67 (P = 0.002). The coefficient of variation of ve was higher in cancers with estrogen receptor negativity than in cancers with estrogen receptor positivity (P < 0.001). The coefficient of variation of ve was also higher in cancers with high Ki-67 than in cancers with low Ki-67 (P < 0.001). The skewness of ve was higher in cancers with high nuclear grade than in cancers with low nuclear grade (P = 0.006). Triple-negative cancers showed higher ve coefficient of variation than did those with luminal A (P < 0.001) and B (P = 0.006). CONCLUSIONS Various ve parameters correlated with breast cancer prognostic factors and molecular subtypes.
Collapse
Affiliation(s)
- Ken Nagasaka
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Shouwa-ku, Nagoya, 466-8550, Japan.
| | - Hiroko Satake
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Shouwa-ku, Nagoya, 466-8550, Japan
| | - Satoko Ishigaki
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Shouwa-ku, Nagoya, 466-8550, Japan
| | - Hisashi Kawai
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Shouwa-ku, Nagoya, 466-8550, Japan
| | - Shinji Naganawa
- Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Shouwa-ku, Nagoya, 466-8550, Japan
| |
Collapse
|
40
|
Gao W, Guo N, Dong T. Diffusion-weighted imaging in monitoring the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis. World J Surg Oncol 2018; 16:145. [PMID: 30021656 PMCID: PMC6052572 DOI: 10.1186/s12957-018-1438-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Accepted: 06/26/2018] [Indexed: 01/22/2023] Open
Abstract
Background Diffusion-weighted imaging (DWI) is suggested as an non-invasive and non-radioactive imaging modality in the identification of pathological complete response (pCR) in breast cancer patients receiving neoadjuvant chemotherapy (NACT). A growing number of trials have been investigating in this aspect and some studies found a superior performance of DWI compared with conventional imaging techniques. However, the efficiency of DWI is still in dispute. This meta-analysis aims at evaluating the accuracy of DWI in the detection of pCR to NACT in patients with breast cancer. Methods Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were drawn to estimate the diagnostic effect of DWI to NACT. Summary receiver operating characteristic curve (SROC), the area under the SROC curve (AUC), and Youden index (*Q) were also calculated. The possible sources of heterogeneity among the included studies were explored using single-factor meta-regression analyses. Publication bias and quality assessment were assessed using Deek’s funnel plot and QUADAS-2 form respectively. Results Twenty studies incorporated 1490 participants were enrolled in our analysis. Pooled estimates revealed a sensitivity of 0.89 (95% CI, 0.86–0.91), a specificity of 0.72 (95% CI, 0.68–0.75), and a DOR of 27.00 (95% CI, 15.60–46.73). The AUC of SROC curve and *Q index were 0.9088 and 0.8408, respectively. The results of meta-regression analyses showed that pCR rate, time duration of study population, and study design were not the sources of heterogeneity. Conclusion A relatively high sensitivity and specificity of DWI in diagnosing pCP for patients with breast cancer underwent NACT treatment was found in our meta-analysis. This finding indicated that the use of DWI might provide an accurate and precise assessment of pCR to NACT.
Collapse
Affiliation(s)
- Wen Gao
- Department of Trauma Surgery, Tianjin Fourth Central Hospital, No.1 Zhongshan Road, Hebei District, Tianjin, 300010, China
| | - Ning Guo
- Department of Breast Surgery, Tianjin Fourth Central Hospital, No.1 Zhongshan Road, Hebei District, Tianjin, 300010, China
| | - Ting Dong
- Department of Cardiovascular Medicine, Guizhou Provincial People's Hospital, No. 83 Zhongshandong Road, Guiyang City, 550002, Guizhou, China.
| |
Collapse
|
41
|
Slanetz PJ, Moy L, Baron P, diFlorio RM, Green ED, Heller SL, Holbrook AI, Lee SJ, Lewin AA, Lourenco AP, Niell B, Stuckey AR, Trikha S, Vincoff NS, Weinstein SP, Yepes MM, Newell MS. ACR Appropriateness Criteria ® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer. J Am Coll Radiol 2018; 14:S462-S475. [PMID: 29101985 DOI: 10.1016/j.jacr.2017.08.037] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Accepted: 08/14/2017] [Indexed: 12/28/2022]
Abstract
Patients with locally advanced invasive breast cancers are often treated with neoadjuvant chemotherapy prior to definitive surgical intervention. The primary aims of this approach are to: 1) reduce tumor burden thereby permitting breast conservation rather than mastectomy; 2) promptly treat possible metastatic disease, whether or not it is detectable on preoperative staging; and 3) potentially tailor future chemotherapeutic decisions by monitoring in-vivo tumor response. Accurate radiological assessment permits optimal management and planning in this population. However, assessment of tumor size and response to treatment can vary depending on the modality used, the measurement technique (such as single longest diameter, 3-D measurements, or calculated tumor volume), and varied response of different tumor subtypes to neoadjuvant chemotherapy (such as concentric shrinkage or tumor fragmentation). As discussed in further detail, digital mammography, digital breast tomosynthesis, US and MRI represent the key modalities with potential to help guide patient management. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Collapse
Affiliation(s)
| | - Priscilla J Slanetz
- Principal Author, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
| | - Linda Moy
- Panel Vice Chair, NYU Clinical Cancer Center, New York, New York
| | - Paul Baron
- Roper St. Francis Physician Partners Breast Surgery, Charleston, South Carolina; American College of Surgeons
| | | | - Edward D Green
- The University of Mississippi Medical Center, Jackson, Mississippi
| | | | | | - Su-Ju Lee
- University of Cincinnati, Cincinnati, Ohio
| | - Alana A Lewin
- New York University School of Medicine, New York, New York
| | - Ana P Lourenco
- Alpert Medical School of Brown University and Rhode Island Hospital, Providence, Rhode Island
| | | | - Ashley R Stuckey
- Women and Infants Hospital, Providence, Rhode Island; American Congress of Obstetricians and Gynecologists
| | | | - Nina S Vincoff
- Hofstra Northwell School of Medicine, Manhasset, New York
| | - Susan P Weinstein
- Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania
| | | | - Mary S Newell
- Panel Chair, Emory University Hospital, Atlanta, Georgia
| |
Collapse
|
42
|
Iima M, Kataoka M, Kanao S, Kawai M, Onishi N, Koyasu S, Murata K, Ohashi A, Sakaguchi R, Togashi K. Variability of non-Gaussian diffusion MRI and intravoxel incoherent motion (IVIM) measurements in the breast. PLoS One 2018; 13:e0193444. [PMID: 29494639 PMCID: PMC5832256 DOI: 10.1371/journal.pone.0193444] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Accepted: 02/12/2018] [Indexed: 01/12/2023] Open
Abstract
We prospectively examined the variability of non-Gaussian diffusion magnetic resonance imaging (MRI) and intravoxel incoherent motion (IVIM) measurements with different numbers of b-values and excitations in normal breast tissue and breast lesions. Thirteen volunteers and fourteen patients with breast lesions (seven malignant, eight benign; one patient had bilateral lesions) were recruited in this prospective study (approved by the Internal Review Board). Diffusion-weighted MRI was performed with 16 b-values (0–2500 s/mm2 with one number of excitations [NEX]) and five b-values (0–2500 s/mm2, 3 NEX), using a 3T breast MRI. Intravoxel incoherent motion (flowing blood volume fraction [fIVIM] and pseudodiffusion coefficient [D*]) and non-Gaussian diffusion (theoretical apparent diffusion coefficient [ADC] at b value of 0 sec/mm2 [ADC0] and kurtosis [K]) parameters were estimated from IVIM and Kurtosis models using 16 b-values, and synthetic apparent diffusion coefficient (sADC) values were obtained from two key b-values. The variabilities between and within subjects and between different diffusion acquisition methods were estimated. There were no statistical differences in ADC0, K, or sADC values between the different b-values or NEX. A good agreement of diffusion parameters was observed between 16 b-values (one NEX), five b-values (one NEX), and five b-values (three NEX) in normal breast tissue or breast lesions. Insufficient agreement was observed for IVIM parameters. There were no statistical differences in the non-Gaussian diffusion MRI estimated values obtained from a different number of b-values or excitations in normal breast tissue or breast lesions. These data suggest that a limited MRI protocol using a few b-values might be relevant in a clinical setting for the estimation of non-Gaussian diffusion MRI parameters in normal breast tissue and breast lesions.
Collapse
Affiliation(s)
- Mami Iima
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
- The Hakubi Center for Advanced Research, Kyoto University, Kyoto, Japan
- * E-mail:
| | - Masako Kataoka
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Shotaro Kanao
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Makiko Kawai
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Natsuko Onishi
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Sho Koyasu
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | - Akane Ohashi
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Rena Sakaguchi
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Kaori Togashi
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
43
|
Short tau inversion recovery in breast diffusion-weighted imaging: signal-to-noise ratio and apparent diffusion coefficients using a breast phantom in comparison with spectral attenuated inversion recovery. Radiol Med 2017; 123:296-304. [PMID: 29230679 DOI: 10.1007/s11547-017-0840-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Accepted: 11/30/2017] [Indexed: 12/25/2022]
Abstract
OBJECTIVE This study aimed to compare the signal-to-noise ratios (SNRs) and apparent diffusion coefficients (ADCs) obtained using two fat suppression techniques in breast diffusion-weighted imaging (DWI) of a phantom. MATERIALS AND METHODS The breast phantom comprised agar gels with four different concentrations of granulated sugar (samples 1, 2, 3, and 4). DWI with short tau inversion recovery (STIR-DWI) and that with spectral attenuated inversion recovery (SPAIR-DWI) were performed using 3.0-T magnetic resonance imaging, and the obtained SNRs and ADCs were compared. ADCs were also compared between the right and left breast phantoms. RESULTS For samples 3 and 4, SNRs obtained using STIR-DWI were lower than those obtained using SPAIR-DWI. For samples 2, 3, and 4, overall ADCs obtained using STIR-DWI were significantly higher than those obtained using SPAIR-DWI (p < 0.001 for all), although no significant difference was observed for sample 1 (p = 0.62). STIR-DWI shows a positive bias and wide limits of agreement in Bland-Altman plot. The coefficients of variance of overall ADCs were good in STIR-DWI and SPAIR-DWI. For all samples, STIR-DWI demonstrated slightly larger percentage differences in ADCs between the right and left phantoms than SPAIR-DWI. CONCLUSION SNRs and ADCs obtained using STIR-DWI are influenced by the T 1 value; a shorter T 1 value decreases SNRs, overestimates ADCs, and induces the measurement error in ADCs. STIR-DWI showed a larger difference in ADCs between the right and left phantoms than SPAIR-DWI.
Collapse
|
44
|
Chu W, Jin W, Liu D, Wang J, Geng C, Chen L, Huang X. Diffusion-weighted imaging in identifying breast cancer pathological response to neoadjuvant chemotherapy: A meta-analysis. Oncotarget 2017; 9:7088-7100. [PMID: 29467952 PMCID: PMC5805538 DOI: 10.18632/oncotarget.23195] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Accepted: 12/01/2017] [Indexed: 12/20/2022] Open
Abstract
Background Diffusion-weighted imaging (DWI) is increasingly used to identify pathological complete responses (pCRs) to neoadjuvant chemotherapy (NAC) in breast cancer. The aim of the present study was to assess the utility of DWI using a pooled analysis. Materials and Methods Literature databases were searched prior to July 2017. Fifteen studies with a total of 1181 patients were included. The data were extracted to perform pooled analysis, heterogeneity testing, threshold effect testing, sensitivity analysis, publication bias analysis and subgroup analyses. Result The methodological quality was moderate. Remarkable heterogeneity was detected, primarily due to a threshold effect. The pooled weighted values were a sensitivity of 0.88 (95% confidence interval (CI): 0.81, 0.92), a specificity of 0.79 (95% CI: 0.70, 0.86), a positive likelihood ratio of 4.1 (95% CI: 2.9, 5.9), a negative likelihood ratio of 0.16 (95% CI: 0.10, 0.24), and a diagnostic odds ratio of 26 (95% CI: 15, 46). The area under the receiver operator characteristic curve was 0.91 (95% CI: 0.88, 0.93). In the subgroup analysis, the pooled specificity of change in the apparent diffusion coefficient (ADC) subgroup was higher than that in the pre-treatment ADC subgroup (0.80 [95% CI: 0.71, 087] vs. 0.63 [95% CI: 0.52, 0.73], P = 0.027). Conclusions DWI may be an accurate and nonradioactive imaging technique for identifying pCRs to NAC in breast cancer. Nonetheless, there are a variety of issues when assessing DWI techniques for estimating breast cancer responses to NAC, and large scale and well-designed clinical trials are needed to assess the technique's diagnostic value.
Collapse
Affiliation(s)
- Wei Chu
- Department of Radiology, Wuxi Huishan District People's Hospital, Jiangsu Province, 214187, China
| | - Weiwei Jin
- Department of Radiology, Wuxi Second Traditional Chinese Medicine Hospital, Jiangsu Province, 214121, China
| | - Daihong Liu
- Department of Radiology, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China
| | - Jian Wang
- Department of Radiology, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China
| | - Chengjun Geng
- Department of Radiology, PLA No.101 Hospital, Wuxi, Jiangsu Province, 214044, China
| | - Lihua Chen
- Department of Radiology, PLA No.101 Hospital, Wuxi, Jiangsu Province, 214044, China
| | - Xuequan Huang
- Department of Radiology, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China
| |
Collapse
|
45
|
While PT, Teruel JR, Vidić I, Bathen TF, Goa PE. Relative enhanced diffusivity: noise sensitivity, protocol optimization, and the relation to intravoxel incoherent motion. MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE 2017; 31:425-438. [PMID: 29110241 DOI: 10.1007/s10334-017-0660-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Revised: 10/17/2017] [Accepted: 10/19/2017] [Indexed: 02/07/2023]
Abstract
OBJECTIVE To explore the relationship between relative enhanced diffusivity (RED) and intravoxel incoherent motion (IVIM), as well as the impact of noise and the choice of intermediate diffusion weighting (b value) on the RED parameter. MATERIALS AND METHODS A mathematical derivation was performed to cast RED in terms of the IVIM parameters. Noise analysis and b value optimization was conducted by using Monte Carlo calculations to generate diffusion-weighted imaging data appropriate to breast and liver tissue at three different signal-to-noise ratios. RESULTS RED was shown to be approximately linearly proportional to the IVIM parameter f, inversely proportional to D and to follow an inverse exponential decay with respect to D*. The choice of intermediate b value was shown to be important in minimizing the impact of noise on RED and in maximizing its discriminatory power. RED was shown to be essentially a reparameterization of the IVIM estimates for f and D obtained with three b values. CONCLUSION RED imaging in the breast and liver should be performed with intermediate b values of 100 and 50 s/mm2, respectively. Future clinical studies involving RED should also estimate the IVIM parameters f and D using three b values for comparison.
Collapse
Affiliation(s)
- Peter T While
- Department of Radiology and Nuclear Medicine, St. Olav's University Hospital, Trondheim, Norway.
| | - Jose R Teruel
- Department of Radiation Oncology, New York University Langone Health, New York, NY, USA.,Department of Radiology, University of California, San Diego, CA, USA.,Department of Circulation and Medical Imaging, Norwegian University of Science and Technology-NTNU, Trondheim, Norway
| | - Igor Vidić
- Department of Physics, Norwegian University of Science and Technology-NTNU, Trondheim, Norway
| | - Tone F Bathen
- Department of Circulation and Medical Imaging, Norwegian University of Science and Technology-NTNU, Trondheim, Norway
| | - Pål Erik Goa
- Department of Radiology and Nuclear Medicine, St. Olav's University Hospital, Trondheim, Norway.,Department of Physics, Norwegian University of Science and Technology-NTNU, Trondheim, Norway
| |
Collapse
|
46
|
Barnes SL, Sorace AG, Whisenant JG, McIntyre JO, Kang H, Yankeelov TE. DCE- and DW-MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer. NMR IN BIOMEDICINE 2017; 30:e3799. [PMID: 28915312 DOI: 10.1002/nbm.3799] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Revised: 08/02/2017] [Accepted: 08/03/2017] [Indexed: 06/07/2023]
Abstract
This work evaluates quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted MRI (DW-MRI) parameters as early biomarkers of response in a preclinical model of triple negative breast cancer (TNBC). The standard Tofts' model of DCE-MRI returns estimates of the volume transfer constant (Ktrans ) and the extravascular extracellular volume fraction (ve ). DW-MRI returns estimates of the apparent diffusion coefficient (ADC). Mice (n = 38) were injected subcutaneously with MDA-MB-231. Tumors were grown to approximately 275 mm3 and sorted into the following groups: saline controls, low-dose Abraxane (15 mg/kg) and high-dose Abraxane (25 mg/kg). Animals were imaged at days zero, one and three. On day three, tumors were extracted for immunohistochemistry. The positive percentage change in ADC on day one was significantly higher in both treatment groups relative to the control group (p < 0.05). In addition, the positive percentage change in Ktrans was significantly higher than controls (p < 0.05) on day one for the high-dose group and on days one and three for the low-dose group. The percentage change in tumor volume was significantly different between the high-dose and control groups on day three (p = 0.006). Histology confirmed differences at day three through reduced numbers of proliferating cells (Ki67 staining) in the high-dose group (p = 0.03) and low-dose group (p = 0.052) compared with the control group. Co-immunofluorescent staining of vascular maturity [using von Willebrand Factor (vWF) and α-smooth muscle actin (α-SMA)] indicated significantly higher vascular maturation in the low-dose group compared with the controls on day three (p = 0.03), and trending towards significance in the high-dose group compared with controls on day three (p = 0.052). These results from quantitative imaging with histological validation indicate that ADC and Ktrans have the potential to serve as early biomarkers of treatment response in murine studies of TNBC.
Collapse
Affiliation(s)
- Stephanie L Barnes
- Institute for Computational and Engineering Sciences, The University of Texas at Austin, Austin, TX, USA
- Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA
| | - Anna G Sorace
- Department of Diagnostic Medicine, The University of Texas at Austin, Austin, TX, USA
- Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, USA
| | - Jennifer G Whisenant
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - J Oliver McIntyre
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA
| | - Hakmook Kang
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Thomas E Yankeelov
- Institute for Computational and Engineering Sciences, The University of Texas at Austin, Austin, TX, USA
- Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA
- Department of Diagnostic Medicine, The University of Texas at Austin, Austin, TX, USA
- Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, USA
| |
Collapse
|
47
|
Abstract
Diffusion-weighted imaging (DWI) holds promise to address some of the shortcomings of routine clinical breast magnetic resonance imaging (MRI) and to expand the capabilities of imaging in breast cancer management. DWI reflects tissue microstructure, and provides unique information to aid in characterization of breast lesions. Potential benefits under investigation include improving diagnostic accuracy and guiding treatment decisions. As a result, DWI is increasingly being incorporated into breast MRI protocols and multicenter trials are underway to validate single-institution findings and to establish clinical guidelines. Advancements in DWI acquisition and modeling approaches are helping to improve image quality and extract additional biologic information from breast DWI scans, which may extend diagnostic and prognostic value.
Collapse
Affiliation(s)
- Savannah C Partridge
- *Department of Radiology, Breast Imaging Section, Seattle Cancer Care Alliance, University of Washington, Seattle, WA †University of Massachusetts Memorial Medical Center, Worcester, MA
| | | |
Collapse
|
48
|
Sorace AG, Harvey S, Syed A, Yankeelov TE. Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting. Semin Oncol Nurs 2017; 33:425-439. [PMID: 28927763 DOI: 10.1016/j.soncn.2017.08.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE To discuss standard-of-care and emerging imaging techniques employed for screening and detection, diagnosis and staging, monitoring response to therapy, and guiding cancer treatments. DATA SOURCES Published journal articles indexed in the National Library of Medicine database and relevant websites. CONCLUSION Imaging plays a fundamental role in the care of cancer patients and specifically, breast cancer patients in the neoadjuvant setting, providing an excellent opportunity for interprofessional collaboration between oncologists, researchers, radiologists, and oncology nurses. Quantitative imaging strategies to assess cellular, molecular, and vascular characteristics within the tumor is needed to better evaluate initial diagnosis and treatment response. IMPLICATIONS FOR NURSING PRACTICE Nurses caring for patients in all settings must continue to seek education on emerging imaging techniques. Oncology nurses provide education about the test, ensure the patient has appropriate pre-testing instructions, and manage patient expectations about timing of results availability.
Collapse
|
49
|
Cho GY, Gennaro L, Sutton EJ, Zabor EC, Zhang Z, Giri D, Moy L, Sodickson DK, Morris EA, Sigmund EE, Thakur SB. Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients. Eur J Radiol Open 2017; 4:101-107. [PMID: 28856177 PMCID: PMC5565789 DOI: 10.1016/j.ejro.2017.07.002] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2017] [Accepted: 07/16/2017] [Indexed: 02/08/2023] Open
Abstract
OBJECTIVE To examine the prognostic capabilities of intravoxel incoherent motion (IVIM) metrics and their ability to predict response to neoadjuvant treatment (NAT). Additionally, to observe changes in IVIM metrics between pre- and post-treatment MRI. METHODS This IRB-approved, HIPAA-compliant retrospective study observed 31 breast cancer patients (32 lesions). Patients underwent standard bilateral breast MRI along with diffusion-weighted imaging before and after NAT. Six patients underwent an additional IVIM-MRI scan 12-14 weeks after initial scan and 2 cycles of treatment. In addition to apparent diffusion coefficients (ADC) from monoexponential decay, IVIM mean values (tissue diffusivity Dt, perfusion fraction fp, and pseudodiffusivity Dp) and histogram metrics were derived using a biexponential model. An additional filter identified voxels of highly vascular tumor tissue (VTT), excluding necrotic or normal tissue. Clinical data include histology of biopsy and clinical response to treatment through RECIST assessment. Comparisons of treatment response were made using Wilcoxon rank-sum tests. RESULTS Average, kurtosis, and skewness of pseudodiffusion Dp significantly differentiated RECIST responders from nonresponders. ADC and Dt values generally increased (∼70%) and VTT% values generally decreased (∼20%) post-treatment. CONCLUSION Dp metrics showed prognostic capabilities; slow and heterogeneous pseudodiffusion offer poor prognosis. Baseline ADC/Dt parameters were not significant predictors of response. This work suggests that IVIM mean values and heterogeneity metrics may have prognostic value in the setting of breast cancer NAT.
Collapse
Affiliation(s)
- Gene Y Cho
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.,Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York School of Medicine, New York, NY, 10016, USA.,Center for Advanced Imaging Innovation and Research (CAI2R), New York University Langone Medical Center, New York, NY, 10016, USA
| | - Lucas Gennaro
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Elizabeth J Sutton
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Emily C Zabor
- Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA
| | - Zhigang Zhang
- Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA
| | - Dilip Giri
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Linda Moy
- Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York School of Medicine, New York, NY, 10016, USA.,Center for Advanced Imaging Innovation and Research (CAI2R), New York University Langone Medical Center, New York, NY, 10016, USA
| | - Daniel K Sodickson
- Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York School of Medicine, New York, NY, 10016, USA.,Center for Advanced Imaging Innovation and Research (CAI2R), New York University Langone Medical Center, New York, NY, 10016, USA
| | - Elizabeth A Morris
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Eric E Sigmund
- Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York School of Medicine, New York, NY, 10016, USA.,Center for Advanced Imaging Innovation and Research (CAI2R), New York University Langone Medical Center, New York, NY, 10016, USA
| | - Sunitha B Thakur
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.,Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| |
Collapse
|
50
|
Chan HM, van der Velden BHM, Loo CE, Gilhuijs KGA. Eigentumors for prediction of treatment failure in patients with early-stage breast cancer using dynamic contrast-enhanced MRI: a feasibility study. ACTA ACUST UNITED AC 2017; 62:6467-6485. [DOI: 10.1088/1361-6560/aa7dc5] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|